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ABSTRACT 
Aminah Wali: Biological characterization of chromatin-targeted small molecules 
(Under the direction of Ian Davis) 
 
Chromatin regulation is commonly disrupted in human cancers. The identification of 
chemical probes that reverse chromatin defects can provide mechanistic insights as well as 
therapeutic opportunities for these cancers. One such cancer is Ewing sarcoma, a pediatric bone 
tumor characterized by the EWSR1-FLI1 fusion protein. EWSR1-FLI1 activates an oncogenic 
transcriptional program by remodeling chromatin at characteristic genomic loci. To identify 
inhibitors of oncoprotein-mediated chromatin modulation, we adapted formaldehyde-assisted 
isolation of regulatory elements (FAIRE) for high-throughput use and screened a library of small 
molecules designed to inhibit a wide range of chromatin regulators.  Among the compounds that 
selectively decreased chromatin accessibility at EWSR1-FLI1 binding sites, the class of histone 
deacetylase inhibitors was highly enriched. We found that treatment with these HDAC inhibitors 
altered both EWSR1-FLI1 transcript and protein levels. In addition, we identified a novel small 
molecule inhibitor of chromatin accessibility, UNC0621. This compound interacts directly with 
chromatin through nuclear protein intermediates. UNC0621 also inhibits the proliferation of 
Ewing sarcoma cells by inducing a cell cycle arrest. These data demonstrate the effect of 
chromatin-targeted small molecules on the biology of Ewing sarcoma cells, and validate the 
potential of chromatin-based assays to screen for compounds with therapeutic potential in 
cancers with epigenetic alterations. 
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Chapter 1: Targeting chromatin regulators in cancer 
1.1: The study of epigenetics mechanisms and chromatin in disease 
Epigenetics refers to changes in gene expression that does not involve changes to the 
underlying DNA sequence. Primarily this concerns the organization of the genome into 
chromatin, which consists of DNA in complex with histone proteins to form nucleosomes (1). 
Chromatin has varying levels of organization, with eukaryotic genomes containing regions of 
highly compacted chromatin as well as regions that are accessible or “open”. Accessible 
chromatin is thought to mark regulatory regions of the genome due to occupation by factors that 
play key roles in the regulation of gene expression (2,3). Chromatin structure is important for 
compaction of DNA within the nucleus, as well as and functional domains that are crucial for 
cell identity and function. Consequently, disruptions in epigenetic regulatory mechanisms can 
result in diseases, and has shown to be involved in the development of many cancers (4).  
Chromatin organization is regulated by various mechanisms and associated proteins. The 
first epigenetic mechanism to be thoroughly studied is DNA methylation, in which the DNA 
itself is methylated by modifying enzymes known as DNA methyltransferases (5). DNA 
methylation generally results in compaction of chromatin and is associated with gene silencing. 
Since the turn of the century, there has been increased study on the role of histone post-
translational modifications (PTMs). The amino-terminal tails of histone proteins can undergo 
various forms of modification, including acetylation, methylation, and phosphorylation. These 
modifications are regulated by enzymes that catalyze the addition or removal of chemical groups, 
broadly termed “writers” and “erasers” respectively, as well as “reader” proteins that bind to 
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modified residues and recruit other regulatory factors (2). Together, the type of modification and 
the residue being modified help dictate downstream regulatory processes and research on the 
roles of specific histone PTMs is ongoing (6). Additionally, chromatin is also regulated by 
chromatin remodeling complexes, which are large and contain several protein subunits (7). 
Chromatin remodeling complexes possess a core subunit with ATPase activity and use energy 
released from ATP hydrolysis to move, exchange, or eject nucleosomes, thereby altering 
chromatin accessibility (8,9). Due to the widespread importance and dynamic nature of these 
processes, studying epigenetic mechanisms in normal development along with their perturbation 
in disease contexts is of great importance. 
Our understanding of how epigenetic mechanisms contribute to cancer progression has 
been greatly increased by pairing biochemical assays with next-generation sequencing 
technologies. Chromatin immunoprecipitation coupled with sequencing (ChIP-seq) has permitted 
detection of genome-wide localization of histone post-translational modifications, which are 
associated with various gene regulatory functions (10,11). Additionally, the chromatin 
architecture of cancer genomes can be directly interrogated through the detection accessible 
regions of chromatin, which represent regulatory regions of the genome. Techniques such as 
DNase-, FAIRE- and ATAC-seq are able to isolate and map accessible regions of chromatin (3). 
These genome-wide chromatin-based assays, often times performed in parallel, have had great 
utility in determining the regulatory landscape of the genome (12).  
While epigenomic approaches have proven essential to studying the chromatin state of 
cancer cells, they alone do not provide the full picture of the mechanisms at play. To better 
understand the cause of chromatin alterations, they can be studied in the context of other 
molecular aberrations that occur in cancer. Modern genomics approaches have allowed for broad 
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mutational analysis of cancer genomes and have shown epigenetic regulators to be highly 
mutated(13–15). Moreover, certain cancers primarily select for chromatin-modulating 
aberrations. For example, clear cell renal cell carcinoma frequently harbors loss or mutation of 
chromatin regulators(16), and loss of a chromatin remodeler is found in nearly all malignant 
rhabdoid tumors (7,17). 
 
1.2: Chromatin regulators as therapeutic targets 
Whereas alterations at the DNA sequence level are considered static, epigenetic 
mechanisms are dynamic and changes in chromatin can persist over cell divisions. 
Understandably, chromatin-modulating proteins have emerged as attractive potential therapeutic 
targets in various cancers (18,19). In recent decades, epigenetically-targeted compounds have 
become widely used in both research and the clinic, with some even becoming FDA-approved 
therapies (20). The first of these was 5’-azacytidine, a DNA methyltransferase inhibitor that was 
approved for patients with myelodysplastic syndrome (21,22). Histone deacetylase (HDAC) 
inhibitors have also seen success in the clinic. Two HDAC inhibitors, Vorinostat and 
Romidepsin, have been approved by the FDA for certain hematological malignancies (23). 
Panbinostat, another HDAC inhibitor, was approved in 2015 for the treatment of multiple 
myeloma (24). Dozens of other chromatin-targeted small molecules are currently used in 
research and clinical trials, and still many more are being developed (20,25–27).  
Although inhibitors for DNA methyltransferases and histone deacetylases have seen 
success, these compounds are also notorious for their pleiotropic effects and lack of clear 
mechanism of their effect on cancer biology (28). Movement towards targeted therapeutic 
approaches has lead to development and application of epigenetic inhibitors based on importance 
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of a target in a particular cancer. EZH2, a methyltransferase and component of the Polycomb 
repressive complex 2 (PRC2), has emerged as an attractive target as gain-of-function mutations 
or overexpression of EZH2 is a feature of several cancers (29). EZH2 inhibitors (EZH2i) are 
currently being utilized to study its role in these cancers, as well as to explore potential 
therapeutic benefit of targeting EZH2 (4,30).  
While significant focus has been on enzymes that modify histones, there is an increasing 
interest in non-enzyme chromatin regulators as potential targets (25). This includes reader 
proteins, which recognize and bind to histone post-translational modifications, thereby 
controlling downstream gene regulatory processes (31). Belonging to this protein class is the 
BET family of readers, which bind to acetyl-lysine residues on histones. BRD4, a member of this 
family, is involved in a recurrent fusion in a rare pediatric carcinoma, leading to the BRD4-NUT 
oncoprotein (32). In an effort to target this fusion protein, the compound JQ1 was developed as 
an inhibitor of BRD4 and was the first of the BET inhibitors (BETi). In addition to being widely 
utilized in research to study the role of BET proteins in cellular processes and cancer models, 
BETi exhibit therapeutic potential and are currently in phase I clinical trials for various 
indications (33–35). The success of BETi and EZH2i represent examples of how development of 
new chromatin-targeted small molecules and identification of new targets is paving way for 
future cancer treatments.  
 
1.3: Targeting EWSR1-FLI1 in Ewing Sarcoma 
One cancer of interest is Ewing sarcoma, a bone and soft tissue sarcoma affecting 
children and young adults for which there are currently no approved targeted therapies (36). 
Interestingly, the cancer is characterized by a genetic aberration that occurs in upwards of 85% 
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of cases: a translocation between chromosomes 11 and 22 that fuses the N-terminal portion of 
EWSR1 to the C-terminal portion of FLI1, generating the EWSR1-FLI1 chimera (37). FLI1 is an 
ETS transcription factor, and the DNA binding domain of FLI1 is retained in EWSR1-FLI1. In 
the context of the fusion protein, the N-terminal domain of EWSR1 functions as a transactivation 
domain, allowing EWSR1-FLI1 to activate an aberrant transcriptional network (38,39). It has 
also been shown that EWSR1-FLI1 activity is necessary for continued growth of Ewing sarcoma 
cells (40,41). Therefore, EWSR1-FLI1 functions as an oncogenic transcription factor and a 
primary driver of Ewing sarcoma.  
To better understand the oncogenic activity of EWSR1-FLI1, a previous study from our 
research group analyzed genomic differences in cells expressing either the parental transcription 
factor FLI1 or the fusion protein. We observed by ChIP-seq that, in spite of retaining the DNA 
binding domain of FLI1, EWSR1-FLI1 exhibited divergent binding across the genome (42). To 
analyze the chromatin organization at EWSR1-FLI1-bound regions, we utilized Formaldehyde-
assisted Isolation of Regulatory Elements (FAIRE), a biochemical assay that selectively isolates 
regions of accessible chromatin. We observed that regions bound by EWSR1-FLI1 in Ewing 
sarcoma cells were characteristically marked by high FAIRE signal, indicating highly accessible 
chromatin. Moreover, upon silencing the fusion gene in Ewing sarcoma cells by RNAi, FAIRE 
signal at EWSR1-FLI1-bound regions decreased. This indicated that EWSR1-FLI1 was 
necessary for maintaining accessible chromatin at its binding sites. Additionally, since many of 
these sites are near EWSR1-FLI1 target genes that are known to contribute to cellular 
transformation, these data suggested that the ability of EWSR1-FLI1 to maintain open chromatin 
is necessary for its oncogenic activity.  
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The pattern of accessibility at oncoprotein-bound sites provided evidence for a unique 
chromatin signature in Ewing sarcoma (42). However, the cause of this phenotype was not 
apparent based on the known functions of the parental proteins. FLI1 belongs to the ETS family 
of transcription factors, and EWSR1 is an RNA binding protein that has also been shown to be 
involved in transcription (43,44). Since neither protein is a known chromatin modifier, the 
mechanism driving increased EWSR1-FLI1-dependent chromatin accessibility in Ewing sarcoma 
remained unclear.  
Due to the presence of the fusion in the vast majority of Ewing sarcoma cases and its 
importance for the biology of the cancer, EWSR1-FLI1 is an attractive potential therapeutic 
target. However, there are gaps in our knowledge of how this protein functions in the cancer, and 
EWSR1-FLI1 is technically challenging to study in a biologically relevant context (45). 
Additionally, because EWSR1-FLI1 is a transcription factor and does not possess “druggable” 
catalytic domains, there are limited options for targeting the fusion protein directly. Rather, 
dependencies and interactions of the oncoprotein present a more promising avenue for 
mechanistic and therapeutic targeting. The chromatin signature we observed in Ewing sarcoma 
cells indicated a potential dependency on epigenetic regulators for EWSR1-FLI1 activity, which 
we hypothesized could be exploited to inhibit oncogene activity. This report describes our 
approach to determine mechanisms important for EWSR1-FLI1-mediated chromatin modulation, 
and my studies on the biological function of compounds that alter chromatin accessibility in 







Chapter 2: A high-throughput small molecule screen identifies inhibitors of aberrant 
chromatin accessibility1 
2.1: Introduction 
A growing range of human cancers has been associated with mutations in genes encoding 
proteins that regulate affect chromatin, the assembly of proteins and DNA that regulates DNA-
templated processes including transcription and replication (15,46). Small molecule drugs and 
chemical probes offer an approach to explore the biological consequences of these mutations and 
are emerging as a therapeutic strategy to target disease pathways.  Drugs targeting histone 
deacetylase enzymes (HDAC), the bromodomain reader BRD4, and DNA methylation have 
already received regulatory approval or have entered clinical testing, and chemical probes have 
been developed against a broad range of chromatin regulators such as the methyltransferases (47) 
DOT1L (48), EZH2 (30,49,50), and G9a (51,52), and the reader proteins L3MBTL3 (53), and 
BRD4 (32,54). Transcription factors that lack enzymatic activity or binding pockets with 
targetable molecular features have been considered “undruggable”, and a reductionist approach 
based on identification of their molecular targets has largely failed.  
The majority of Ewing sarcoma, a highly malignant pediatric bone and soft tissue tumor, 
harbors the chromosomal translocation t(11;22)(q24;q12), which joins the amino terminal  
              
1 This work was previously published in the Proceedings of the National Academy of the 
Sciences. Pattenden SG, Simon JM, Wali A, Jayakody CN, Troutman J, McFadden AW, Wooten 
J, Wood CW,  Frye SV, Janzen WP, Davis IJ. High-throughput small molecule screen identifies 
inhibitors of aberrant chromatin accessibility. Proc Natl Acad Sci. 2016 Feb 29;201521827. 
Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.1521827113 
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domain of EWSR1 with the DNA binding domain of the ETS transcription factor family member 
FLI1 to generate the chimeric transcription factor EWSR1-FLI1 (55). Translocations with other 
ETS genes are detected in most of the remaining tumors yielding similarly functioning fusion 
proteins (37). We recently found that, despite conservation of the ETS DNA binding domain, the 
fusion oncoprotein uniquely localizes to specific microsatellite regions (42,56). Using 
formaldehyde-assisted isolation of regulatory elements (FAIRE), a biochemical strategy to 
enrich for nucleosome depleted regions of chromatin, we demonstrated that EWSR1-FLI1 
binding was necessary to maintain nucleosome depletion at these sites. The mechanism through 
which EWSR1-FLI1 modifies chromatin remains unknown. EWSR1-FLI1 does not possess 
recognizable catalytic activity, so other yet-to-be-identified proteins likely mediate its ability to 
remodel chromatin.  
The absence of a biochemical mechanism would typically pose challenges for chemical 
targeting. However, we hypothesized that reversing a unique chromatin signature could serve as 
a strategy to discover small molecules with activity toward EWSR1-FLI1. To target this activity, 
we adapted and validated FAIRE as an automated, high-throughput tool and applied this method 
to evaluate a focused set of small molecules designed to interact with proteins that regulate 
chromatin. Because this approach directly assessed the effects of compounds on a specific, 
disease-associated aberrant chromatin signature, while remaining agnostic about precise 
molecular mechanisms, it enabled the discovery of agents that affect the underlying molecular 
defect without requiring an a priori selection of molecular targets.  
 
2.2: Validation of column-based FAIRE 
As currently applied, FAIRE, a biochemical assay for the enrichment of nucleosome- 
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depleted regions of the genome, is dependent on organic extraction with a mixture of phenol and 
chloroform. Since this critical extraction step is not easily automated, we adapted and 
miniaturized FAIRE by substituting organic extraction with solid-phase selection and robotic 
automation, hereafter termed high throughput FAIRE (HT-FAIRE) (Fig. 2.1A).  Since the 
chromatin fractionation step is central to this technique, we compared the performance of these 
methods. Quantitative locus-specific testing demonstrated that both approaches offered 
concordant enrichment at a series of promoter and enhancer regions (Fig. 2.2). We then 
compared the performance of both methods genome-wide. For these studies we used primary 
human endothelial cells (HUVEC) since multiple genomic datasets exploring chromatin features 
have been generated for these cells permitting subsequent integrative analyses of the FAIRE 
results (ENCODE Tier 2,  (12)).HT-FAIRE signal mimicked that of standard FAIRE. 
Enrichment at active transcriptional start sites (TSS) positively correlated with RNA abundance, 
as well as enrichment at CTCF sites, consistent with previously described FAIRE studies (Fig. 
2.1B-D) (57). Signal enrichment by HT-FAIRE was less robust at TSS, consistent with the qPCR 
results. Of the top 10,000 nucleosome-depleted regions detected in HUVEC by HT-FAIRE, 
approximately 90% overlapped those sites identified by standard FAIRE. In contrast, fewer than 
50% of enriched regions overlapped FAIRE sites from any of six other cell lines (Fig. 2.3A), 
demonstrating that HT-FAIRE offers a level of specificity similar to that reported in previous 
studies that compared standard FAIRE between cell types (58). 
We then specifically examined those genomic regions that most discriminate HT- and 
standard FAIRE and also demonstrate HUVEC cell-type specificity. Hierarchical clustering of 
these ~9,700 genomic regions identified three groups. Cluster 1 (1,805 regions) consisted of 
those regions with FAIRE enrichment in all cell lines examined by standard FAIRE but lacked 
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signal in HT-FAIRE. Cluster 2 (6,017 regions), by far the largest, consisted of regions with 
HUVEC-specific signal enrichment that was detected by both HT- and standard FAIRE. Cluster 
3 (843 regions) consisted of regions selectively identified by HT-FAIRE (Fig. 2.1F). Regions in 
each cluster were then associated with genes (Genome Regions Enrichment of Annotations Tool 
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Figure 2.1: Comparison of FAIRE methodologies. (A) Flow diagram comparing column-
based and standard FAIRE methods.  (B) Heatmap representation of normalized FAIRE 
enrichment (± 3 kb from TSS) using standard (left) or column (right) FAIRE in HUVEC. (C) 
Normalized FAIRE signal from both methods ± 3 kb from TSS. (D) Normalized FAIRE 
signal from both methods ± 3 kb around HUVEC CTCF sites (ENCODE). (E) Fraction of top 
10,000 HT-FAIRE enriched sites overlapping standard FAIRE sites from HUVEC and 6 other 
cell types (ENCODE). (F) Hierarchical clustering analysis of 500 bp intervals demonstrating 
differential FAIRE signal across 7 cell types as well as HUVEC HT-FAIRE. Platform-





As expected, the HUVEC-selective sites detected by both HT- and standard FAIRE 
(Cluster 2) were tightly linked with endothelial cell ontologies including angiogenesis (q = 4.4 x 
10-12) and regulation of cell-substrate adhesion (q = 6.5 x 10-7) (Fig. 2.3B). No significant gene 
ontologies were associated with the regions in the other clusters. To test whether FAIRE-
enriched regions were likely to harbor regulatory elements, we annotated the sites from each 
cluster with active (H2A.Z, H3K4me1, H3K4me2, H3K4me3, H3K9ac, H3K27ac, H3K36me3, 
H3K79me2, H4K20me1) and repressive histone modifications (H3K9me1, H3K9me3, 
H3K27me3). We also tested association with numerous transcription factors that are known to be 
important in endothelial cell biology (CTCF, RNA Polymerase II, MAX, FOS, JUN, GATA2, 
FLI1, EZH2) as assessed by ChIP-seq (12,42) (Fig 2.1F). Sites in Cluster 2 (common to both 

























Figure 2.2: Comparison of standard versus HT-FAIRE by quantitative PCR (qPCR). 
Chromatin was prepared from endothelial (HUVEC) cells and divided in half, and input was 
reserved. Each half was subjected to standard (black bars) or column-based (gray bars) 
FAIRE followed by qPCR. Primer sets included regions that are negative (Negative) for 
FAIRE signal, promoter regions (Promoter) from actively transcribed genes, and enhancer 
regions (Enhancer) (Table 2.3). Percent input (ΔCt) values were normalized to a genomic 
region near the PRPF31 gene that is negative for FAIRE signal. Error bars represent the SE 
of two biological replicates with two technical replicates each. 
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platforms, HUVEC-specific) were associated primarily with active histone modifications as well 























































































































































































































































































































































































































































































































































































The prevalence of putative FLI1 and FOS/JUN binding sites was corroborated by the 
enrichment of ETS and AP1 DNA sequence motifs in these regions (p < 1 x 10-800, Fig. 2.3C). 
ETS (specifically ETV2) and AP1 factors are both known to play prominent roles in endothelial 
development (60,61). Regions in cluster 1 were more closely associated with repressive 
modifications and EZH2 binding (Fig 2.1F). Clusters 1 and 3 were distinguished by enrichment 
for repetitive regions, with each cluster associated with a specific repetitive element class: 
satellites (82% of Cluster 1 sites) and simple repeats (71% of Cluster 3 sites) (Fig. 2.3D). We 
also noted a difference in sequence composition between Cluster 1 and Clusters 2 and 3 (Fig. 
2.3E). The basis of their differential enrichment may reflect chromatin variation at these regions 
that are distinguished by the biochemical properties specific to organic or solid phase 
purification. Because we used published standard FAIRE datasets that were generated with a 
shorter sequencing read length (ENCODE, 36-bp reads), we asked whether the difference in read 
length could partially account for the variability in mapping and sequence content at Clusters 1 
and 3 (Fig. 2.3F). Repeating these analyses after truncating the HT-FAIRE sequencing reads to 
Figure 2.3: Comparison of FAIRE methodologies. (A) Fraction of top 10,000 HT-FAIRE 
enriched sites overlapping standard FAIRE sites from HUVEC and six other cell types 
(ENCODE). (B) Ontology enrichment (GREAT) of genes associated with sites in clusters 1–3 
(Fig. 2.1E )(C) Highly enriched TF motifs in cluster 2. Clusters 1 and 3 did not have any 
motifs determined to be significant by a multicomponent test (Methods). (D) Mappability 
(Left) and nucleotide content (Right) within 1.5 kb of sites from clusters 1–3 (Fig. 2.1E). 
Mappability was assessed for both 36- and 50-bp reads. Genomic redundancy refers to the 
number of times a given 36- or 50-mer occurs in the reference genome. 500 bp window 
indicated by bar. (E) Fractional overlap annotation of clusters 1–3 (Fig. 2.1E) with repetitive 
element classes. (F) Fractional overlap annotation of clusters 1–3 (H) with histone 
modifications and transcription factor ChIP-seq peak calls (ENCODE). (G) Fractional overlap 
annotation of clusters 1–3 (H) with repetitive element classes (RepeatMasker). (H) 
Hierarchical clustering analysis of ENCODE FAIRE signal in 500-bp intervals from seven 
cell types, as well as HUVEC HT-FAIRE after truncation of 50-bp reads to 36 bp. Identified 
clusters exhibit method specificity (clusters 1 and 3) and cell-type specificity (cluster 2). 
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36 bp did not change the hierarchical clustering or histone modification associations (Fig. 2.3 G 
and H). Taken together these data demonstrate that HT-FAIRE performs similarly to standard 
FAIRE and identifies regions that are biologically meaningful. 
 
2.3: Application of HT-FAIRE to small molecule screening  
After validating solid phase purification we adapted the method for high throughput 
automation and applied it in a targeted screen. The screen was based on two regions (P1 and P7) 
that were selected from a set of Ewing sarcoma-specific sites a region that we had previously 
shown was were aberrantly accessible in multiple Ewing sarcoma cell lines with accessibility 
that was dependent on continued expression of EWSR1-FLI1 (42). Two control regions that 
consistently demonstrate FAIRE enrichment (AURKAIP1) or lack of enrichment (BC006361) 
across many cell types were also tested. We performed the screen using a custom library that 
consisted of 640 small molecules, including those designed to target histone methyltransferases, 
methyl lysine reader proteins, histone demethylases and deacetylases, DNA methyltransferases, 
and acetyl-lysine reader proteins.  A Ewing sarcoma patient-derived cell line that grows in 
suspension culture (EWS894) was first tested for DMSO tolerance (Fig. 2.4). The unit 
automation pipeline separated each of two 384-well compound plates containing the library into 
four 96-well plates for screening (Fig. 2.5). Cells were then exposed to 10 μM of each compound 
(or DMSO control) for 16 hours. Following HT-FAIRE, samples from the 96-well plates were 
combined into a 384-well plate format for qPCR-based testing of the signature and control 
regions in two technical replicates.  The positive control region demonstrated a statistically 
significant difference in FAIRE signal over the background control (Plate 1, p = 7.50e-53; Plate 
































































Figure 2.4: EWS894 cell number and DMSO tolerance for HT-FAIRE assay. (A) Assay 
showing cell viability at increasing cell density in a 96-well plate after 16-h incubation. A 
plating density of 1.1 × 105 cells per well was selected for the assay (dotted line). The x axis 
shows cell number. The y axis shows the average luminescent signal over background (media 
only). Error bars represent the SD of three replicates. (B) Assay showing cell viability after 
16-h treatment of 1.1 × 105 EWS894 cells per well with twofold dilutions of DMSO ranging 
from 1% to 0.03125%. Cells begin to lose viability at DMSO concentrations higher than 0.1% 
(dotted line). The x axis shows the LOG2-transformed percent DMSO concentration. 
The y axis shows the average luminescent signal over background (no DMSO). Error bars 
represent the SD of three replicates. 
	 16	
  
1 2 3 4 5 6 7 8 9 10 11 12
A Input Compound1 Compound2 Compound3 Compound4 Compound5 Compound6 Compound7 Compound8 Compound9 Compound 10 DMSO
B Input Compound 11 Compound 12 Compound 13 Compound 14 Compound 15 Compound 16 Compound 17 Compound 18 Compound 19 Compound 20 DMSO
C Input Compound 21 Compound 22 Compound 23 Compound 24 Compound 25 Compound 26 Compound 27 Compound 28 Compound 29 Compound 30 DMSO
D Input Compound 31 Compound 32 Compound 33 Compound 34 Compound 35 Compound 36 Compound 37 Compound 38 Compound 39 Compound 40 DMSO




























384-well plate, 320 compounds per plate
Four 96-well plates
Incubate cells with 10 µM compound
16 hours
Crosslink cells, wash, resuspend in FAIRE buffer
Transfer to sonication 96-well plate Sonicate to fragment chromatin
Add RNase
Manually remove samples from column 1 and pool for input
Transfer from sonication plate to column
Extract DNA, dilute 1:1000
Bind samples and wash
Elute DNAAdd Input to A1 and elution buffer control to B1
Compress four 96-well plates to one 384-well plate









1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
A Input1 Input2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 DMSO1 DMSO2
B Input3 Input4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 DMSO3 DMSO4
C NTC1 NTC2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 DMSO1 DMSO2
D NTC3 NTC4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 DMSO3 DMSO4
E 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 DMSO1 DMSO2
F 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 DMSO3 DMSO4
G 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 DMSO1 DMSO2
H 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 DMSO3 DMSO4
I 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 Control1 Control2
J 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 Control3 Control4
K 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 Control1 Control2
L 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 Control3 Control4
M 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 Control1 Control2
N 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 Control3 Control4
O 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 Control1 Control2
P 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 Control3 Control4
Figure 2.5: Flowchart outlining the automation steps for HT-FAIRE. 
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concordant (Pearson r = 0.8764), which supported combining the values from both sites for 
subsequent analytics (Fig. 2.6A).   
 
 
To quantify the degree to which chromatin accessibility changed following compound 












































































Figure 2.6: Chromatin signature-based screen identified a cluster of HDAC inhibitors 
that significantly decreased EWSR1-FLI1-dependent chromatin accessibility.  (A) The 
LOG10 transformed relative chromatin inhibition (RCI) scores for the Ewing sarcoma specific 
P1 and P7 regions are plotted.  Since they showed a strong correlation (Pearson r = 0.8764) 
these values were averaged for the final RCI score.  (B) RCI scores for DMSO and a negative 
control compound, UNC0638 are plotted for each 384-well plate.  An RCI score of 1.0 
indicates no change (dotted line).  Error bars are the standard deviation of 16 replicate 
samples.  (C-D) The chromatin-focused library consists of two 384-well compound plates 
(640 compounds total).  Plate 1 (C) or Plate 2 (D) LOG2 ratio of the relative chromatin 
inhibition values was plotted against the rank order of compounds from greatest relative 
decrease (top, left side of X-axis) to the greatest relative increase (top, right side of X-axis) in 
FAIRE signal following compound treatment.  The dashed lines indicate the significance 
cutoff of relative chromatin inhibition values greater or less than two standard deviations from 
the average RCI for vehicle-treated controls.  Thirty compounds that show the greatest 
decrease in FAIRE signal for each plate are magnified (bottom graph).  The bars representing 
HDAC inhibitors are highlighted in magenta.   
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enrichment at the oncogene-targeted regions to that at the positive control region. Compounds 
that affected both the oncogene-targeted and controls regions were considered non-specific. A 
RCI score of 1.0 was considered “no change”.  Replicates of controls DMSO (vehicle) and 
UNC0638 (26) (a chemical probe that we had previously determined not to affect aberrantly 
open chromatin in Ewing sarcoma cells) demonstrated an RCI of 1.0 (Figs. 2.6B and S5A).  
Since this primary screen was based on a single measurement, we permitted greater intersample 
variability, defining compounds with an RCI value greater than two SDs from the mean RCI 
score for DMSO-treated controls as “hits” (Figs. 2.6B and S5A) (62). Fifty-eight compounds met 
criteria for reduced chromatin accessibility (Fig. 2.6C-D).  Forty-three of these compounds were 
uncharacterized, 14 of which were analogs within a single chemical scaffold, and 15 were 
characterized chemical probes. Treatment with 20 compounds resulted in increased FAIRE 
signals, all of which were uncharacterized (Table 2.1). Because the goal of this study was to 
inhibit EWSR1-FLI1-mediated aberrant chromatin accessibility, we focused on those compounds 
that decreased the FAIRE signal.  
We then prepared a secondary screen plate that contained these compounds and 16 
compounds that failed to show a change in chromatin accessibility in the initial screen (RCI of 
1.0, no change).  This secondary screen was performed on three independent replicates of 
EWS894 cells, permitting us a more stringent threshold of 3 SDs from the mean RCI score to 
define hits (62,63)   Fifteen compounds (26%) met this enhanced threshold (Fig 2.8A and S5B). 
Remarkably, of the 21 HDAC inhibitors that were included in our library, 14 of these 
compounds scored as hits in both the primary and secondary screens (Fig. 2.8A).  We compared 
the specificity of the active and inactive HDAC inhibitors (Table 2.2).  Although the majority of 
the inhibitors in our set have known activity against multiple HDAC proteins making it difficult  
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Supplementary Table 1 - Compounds that produced a statistically significant change in FAIRE signal




methyl lysine reader uncharacterized 8
DNA methyltransferase chemical probe 1
lysine methyltransferase uncharacterized 16
methyl lysine reader uncharacterized 6
lysine methyltransferase uncharacterized 6
histone deacetylase chemical probe (Table S2) 14
methyl lysine reader uncharacterized 10
lysine methyltransferase uncharacterized 6
arginine methyltransferase uncharacterized 3
methyl lysine reader uncharacterized 5







Figure 2.7: Cutoff values for HT-
FAIRE screen hits. (A) Compounds 
were assigned as a hit for the HT-
FAIRE screen if they had an RCI 
score of ≤2 SDs from the average 
DMSO RCI score. (B) Compounds 
were assigned as a hit in the HT-
FAIRE secondary screen if they had 
an RCI score of ≤3 SDs form the 
average DMSO RCI score. 
 
Table 2.1: Compounds that produced a statistically significant change 
in FAIRE signal 
 
	 20	
to identify the specific HDAC target, inhibitors selective for HDAC6 (Tubastatin) (64) and 
HDAC8 (PCI-34051) (65) did not score in our screen, making it unlikely that either of these 
HDAC proteins are involved in maintaining aberrant chromatin accessibility in Ewing sarcoma.  
The overall reproducibility of the screen and in particular for HDAC inhibitors in the secondary 
screen confirms the robustness of HT-FAIRE as an approach for discovering biologically 
relevant compounds using a small, focused compound library.  A priori selection of inhibitors of 
HDAC proteins as lead candidates for screening would have been unlikely since histone 
hyperacetylation is commonly associated with destabilized nucleosomes and open chromatin. To 
replicate the results of the screen, we focused on 2 hit compounds, Vorinostat and Panobinostat, 
since these hydroxamate derivatives inhibit multiple classes of HDACs and have received FDA 
approval for oncological indications (66). Treatment of EWS894 cells for 16 hours with either of 
these compounds followed by HT-FAIRE resulted in a dose-dependent decrease in chromatin 
accessibility (Fig. 2.8A). This decrease was not observed with an HDAC inhibitor that did not 
score as a hit in our screen (Tubastatin), or a compound with an unrelated structure and protein 
target. 
We then validated the compounds that emerged from our screen using standard FAIRE-
qPCR. FAIRE signal from cells treated for 16 hours with Panobinostat decreased at the test 
regions to a similar extent (~2-fold) to that observed in the screen, and also demonstrated a 
similar effect on two additional EWSR1-FLI1-targeted sites (Fig. 2.8B). Critically, positive 
control regions remained unaffected, demonstrating that the decreased RCI was not the result of 
increased signal at the control regions.  We then validated the effect of additional HDAC 
inhibitors by standard FAIRE. Panobinostat, Vorinostat and AR-42 demonstrated a similar 




HDAC inhibitor Hit? HDAC Target References
Panobinostat (LBH-589) Yes HDAC1, HDAC2, HDAC3, HDAC6 Blood. 2005 Feb 15;105(4):1768-76.
AR-42 (HDAC-42) Yes Pan inhibitor J Med Chem. 2005 Aug 25;48(17):5530-5.
Trichostatin A (TSA) Yes Pan inhibitor J Biol Chem. 1990 Oct 5;265(28):17174-9.
Vorinostat (SAHA) Yes HDAC1, HDAC2, HDAC3, HDAC6 Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7.
Entinostat (MS-275) Yes HDAC1, HDAC2, HDAC3, HDAC9 Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7.
Abexinostat (PCI-24781) Yes HDAC1, HDAC2, HDAC3, HDAC6, HDAC10 Mol Cancer Ther. 2006 May;5(5):1309-17.
Dacinostat (NVP-LAQ824) Yes HDAC1, HDAC3, HDAC4, HDAC6 Blood. 2003 Oct 1;102(7):2615-22. Epub 2003 Jun 19; Cancer Res. 2004 Jan 15;64(2):689-95.
Quisinostat (JNJ-26481585) Yes Pan inhibitor Leukemia. 2009 Oct;23(10):1894-903. 
CUDC-101 Yes Pan-HDAC, EGFR, HER2 J Med Chem. 2010 Mar 11;53(5):2000-9.
Pracinostat (SB939) Yes Pan inhibitor Mol Cancer Ther. 2010 Mar;9(3):642-52.
Givinostat (ITF2357) Yes HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7 J Hepatol. 2005 Feb;42(2):210-7.
CUDC-907 Yes Pan-HDAC and PI3K Clin Cancer Res. 2012 Aug 1;18(15):4104-13
M344 Yes Pan inhibitor J. Med. Chem., 1999, 42 (22), pp 4669–4679
Romidepsin (FK228) Yes HDAC1, HDAC2, HDAC3, HDAC8 J Antibiot (Tokyo). 1994 Mar;47(3):301-10.
Tubastatin HCl No (Negative Control) HDAC6 J Am Chem Soc. 2010 Aug 11;132(31):10842-6
Belinostat (PXD101) No HDAC1, HDAC2, HDAC3, HDAC6 Mol Cancer Ther. 2003 Aug;2(8):721-8.
Mocetinostat (MGCD0103) No HDAC1, HDAC2 Mol Cancer Ther. 2008 Apr;7(4):759-68
Droxinostat No HDAC3, HDAC6, HDAC8 Mol Cancer Ther. 2010 Jan;9(1):246-56.
MC1568 No HDAC4, HDAC5, HDAC7, HDAC9 J Med Chem. 2005 May 5;48(9):3344-53.
PCI-34051 No HDAC8 Leukemia. 2008 May;22(5):1026-34.
Tacedinaline (CI-994) No HDAC1, HDAC2, HDAC3 Cancer Res. 1993 Jul 1;53(13):3008-14; Mol Cancer Ther. 2003 Apr;2(4):401-8.
Table 2.2: Histone deacetylase inhibitors included in the compound library. Histone 
deacetylase inhibitors, specification of screening status, and recognized HDAC target 
specificity are shown. 
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FAIRE signal at an EWSR1-FLI1 targeted site (Fig. 2.8D).  As further validation, we performed 





lines, EWS502 (Fig. 2.8B) and RD-ES (Fig. 2.8C). Panobinostat treatment for 16 hours 
significantly decreased FAIRE signal at EWSR1-FLI1 binding sites in both of these cell lines. 
Together, these data confirm that HDAC inhibitors are associated with reduced chromatin 
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Figure 2.8: HDAC inhibitors affect 
EWSR1-FLI1 chromatin accessibility in a 
dose-dependent manner.  (A) Secondary 
screen that included all hit compounds from 
Plate 1 and Plate 2 and a selection of 
compounds that did not score.  LOG2 ratio of 
the RCI values as described for Fig. 2C-D.  
The dashed lines indicate the significance 
cutoff of RCI values greater or less than three 
standard deviations from the average RCI for 
vehicle-treated controls.  The bars 
representing HDAC inhibitors are 
highlighted in magenta.  (B) Standard 
FAIRE-qPCR was performed on EWS894 
cells treated with Panobinostat for EWSR1-
FLI1 target sites and control sites (C) 
Standard FAIRE-qPCR was performed on 
EWS894 cells treated with Vorinostat, AR-
42, or Panobinostat. (D) FAIRE-qPCR was 
performed on an EWSR1-FLI1 binding site 
(P1) and a control site (AURKAIP1) after 
treatment of EWS894 cells with DMSO or 
10-fold dilutions of Panobinostat (10 μM to 
0.01 μM). All treatments were 10 µM for 16 
h unless otherwise noted. FAIRE is plotted 
relative to DMSO control, and error bars 
represent the SD of three replicates. 






To explore the mechanism underlying the chromatin signature reversal, we asked whether 
EWSR1-FLI1 levels were affected by HDAC inhibitor treatment. Panobinostat and Vorinostat 
treatment resulted in a dose-dependent decrease in EWSR1-FLI1 mRNA levels, while Tubastatin 
had no effect (Fig. 2.10A).  Consistent with the decrease in mRNA, EWSR1-FLI1 protein levels 
were also decreased following treatment with Panobinostat and Vorinostat (Fig. 2.10B).  
Tubastatin did not affect EWSR1-FLI1 protein levels although a slight overall decrease was 


















































































Figure 2.9: HDAC inhibition 
selectively decreases chromatin 
accessibility at EWSR1-FLI1 
binding sites. (A) HT-FAIRE-
qPCR at the same genomic 
regions used for the original 
screen was conducted after 
treatment of EWS894 cells for 16 
h with threefold dilutions of 
Vorinostat, Panobinostat, 
Tubastatin, or a control 
compound in concentrations 
ranging from 10 to 0.0005 μM. 
Error bars represent the SE of two 
biological replicates with two 
technical replicates each. FAIRE-
qPCR at EWSR1-FLI1 target sites 
and control site after Panobinostat 
treatment of (B) EWS502 or (C) 
RD-ES cells. EWSR1-FLI1 
targets sites were P1 and P7 for B 
and C. Control FAIRE site was 
AURKAIP1 for B and C. All 
treatments were at 10 µM for 16 h 
unless otherwise noted. FAIRE is 
plotted relative to DMSO control 
and error bars represent the SD of 
three replicates. 
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compounds identified in the HT-FAIRE screen, decrease levels of EWSR1-FLI1 by altering 
transcription.  
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We then asked whether ectopically expressed EWSR1-FLI1 would be similarly affected 
by HDAC inhibition.  We generated a Ewing sarcoma cell line in which the endogenous 
EWSR1-FLI1 was silenced with concurrent stable expression of lentivirally transduced EWSR1-
FLI1.  Panobinostat or Vorinostat treatment of these cells did not affect EWSR1-FLI1 mRNA 
levels (Fig. 2.10C). Correspondingly, treatment with multiple HDAC inhibitors had virtually no 
effect on exogenous EWSR1-FLI1 protein levels (Fig. 2.10D), in contrast to the endogenous 
protein (Fig. 2.11A). These data demonstrate that HDAC inhibition acts through transcription of 
the EWSR1-FLI1 without affecting protein stability. 
We then tested chromatin accessibility in the EWSR1-FLI1-transduced Ewing sarcoma 
cells. Treatment with multiple HDAC inhibitors failed to affect FAIRE signal at oncogene-
targeted regions (Fig. 2.10E). These results were replicated in a second Ewing sarcoma cell line 
(EWS502) that similarly ectopically expresses EWSR1-FLI1 (Fig. 2.11B). Taken together, these 
data imply that the loss of chromatin accessibility at EWSR1-FLI1 binding sites results from 
HDAC inhibition-mediated alterations in EWSR1-FLI1 transcription, thereby suppressing 
oncoprotein levels, rather than HDAC activity directly at the chromatin target sites.   
 
Figure 2.10: EWSR1-FLI1 mRNA and protein levels are decreased after HDAC 
inhibition. (A) EWSR1-FLI1 mRNA levels were measured by qRT-PCR after treatment of 
EWS894 cells with indicated concentrations of Panobinostat, Vorinostat, or Tubastatin. (B) 
EWS894 cells were treated with varying concentrations of Panobinostat, Vorinostat, or 
Tubastatin (threefold dilutions, 10 μM to 0.001 μM). Cell extracts were assayed for 
EWSR1-FLI1 (“E-F”) and tubulin protein levels by immunoblot. All treatments were for 16 
h. (C) EWS894 cells lentivirally transduced with EWSR1-FLI1 were treated with varying 
concentrations of Panobinostat or Vorinostat. RNA was measured by qRT-PCR. (D) 
Transduced EWSR1-FLI1 protein levels were measured in EWS894 cells after treatment 
with HDAC inhibitors (10 µM) by immunoblotting. (E) FAIRE-qPCR measuring chromatin 
accessibility in EWS894 cells with exogenous EWSR1-FLI1 after treatment with 10 μM 
multiple HDAC inhibitors. All treatments were for 16 h. Error bars represent the SD of 






We have adapted and validated FAIRE as a high-throughput, automated assay for 
chromatin accessibility. Applying this method to screen a chromatin-focused chemical library 
enabled the identification of compounds that alter a disease-specific chromatin signature.  Based 
on this screen we demonstrated a role for HDACs in the transcription of the central oncogenic 
protein, EWSR1-FLI1, thereby defining a potential chromatin regulatory mechanism involved in 
Ewing Sarcoma.  
In contrast to previous efforts to inhibit EWSR1-FLI1 activity that have capitalized on 
individual target gene expression or physical interactions (67–70)the application of HT-FAIRE 
offered a strategy to identify therapeutics based on variation in chromatin accessibility, a 
universal genomic feature determined by the combined effects of transcriptional regulators and 
















































Figure 2.11: Chromatin effects of HDAC inhibition are dependent on HDAC-
mediated transcriptional changes. (A) Endogenous EWSR1-FLI1 protein levels were 
measured in EWS894 cells after treatment with HDAC inhibitors (10 µM) by 
immunoblotting. (B) FAIRE-qPCR EWS502 cells with exogenous EWSR1-FLI1 treated 
with 10 μM Panobinostat. EWSR1-FLI1 targets sites were P1 and P7, and control FAIRE 
site was AURKAIP1. All treatments were for 16 h. Error bars represent the SD of three 
biological replicates (A) or three technical replicates (B). 
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not depend on the prior selection of a specific target.  Without the need for an enzymatic 
processing step, FAIRE does not require the optimization (and consequent variability) associated 
with DNase, MNase, or Assay for Transposase-Accessible Chromatin (ATAC) (3) other 
techniques that explore chromatin accessibility.  A specific chromatin signature associated with 
multiple molecular mechanisms can form the basis for an HT-FAIRE functional screen.  
The connection between HDAC activity and EWSR1-FLI1 had been noted previously.  
Romedepsin, also a hit in our screen, had been shown to decrease EWSR1-FLI1 mRNA levels 
and also had a profound anti-proliferative activity on Ewing cells (72). In a separate study, 
Vorinostat treatment reversed the EWSR1-FLI1-mediated transcriptional activation signature in 
Ewing sarcoma cells but not the repressive gene signature. Our data are consistent with these 
findings since HDAC inhibition primarily affects those genes regulated by EWSR1-FLI through 
the GGAA-containing microsatellite repeats, a relationship associated with gene activation. 
Indeed, our screen focused on these microsatellite regions.  
The role of HDAC activity in transcription is complex.  HDAC proteins are the catalytic 
subunits of multiple co-repressor complexes including Sin3A, NuRD, NCoR/SMRT, and 
CoREST (73). Recent evidence suggests the SP1 transcription factor directly binds to the 
EWSR1-FLI1 promoter and positively regulates transcription. Although SP1 has been shown to 
interact with HDAC1 and HDAC2, this interaction mediates repression, in contrast to the activity 
noted in this study (74). HDAC-containing complexes are also known to function in 
transcriptional elongation and may selectively affect highly expressed genes in cancers (75).  
 In conclusion, we developed an approach to screen compounds based on changes in 
chromatin.  HT-FAIRE is applicable to any cellular model associated with a specific chromatin 
accessibility signature and offers a general strategy to disrupt the function of proteins lacking 
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structure amenable to small molecule targeting or the absence of complete characterization of the 
biochemical pathways and partners.  The chemical probes identified by this method can offer 
mechanistic insights into chromatin dysregulation in disease, lead to the identification of valid 
molecular targets, and serve as starting points for drug discovery efforts.  
 
2.5: Methods 
Cell Culture and Western Analysis. 
EWS894 and EWS502 cells (76) were cultured in RPMI-1640 supplemented with 15% 
(vol/vol) FBS and maintained at standard growth conditions of 37 °C and 5% CO2. Proteins were 
extracted using 2× Laemmli buffer, were separated by SDS/PAGE, and were then transferred 
onto nitrocellulose and probed for EWSR1-FLI1 (ab15289; Abcam) or tubulin (T9026; Sigma) 
and fluorescent secondary antibodies and quantified (LiCor). 
 
Standard FAIRE, HT-FAIRE 
FAIRE for sequencing was as follows: Replicate samples of chromatin from 2 × 107 cells 
were divided. Equal portions were used for standard FAIRE, as described or HT-FAIRE, using a 
ChIP DNA clean and concentrate column (11-379; Zymo Research) as per the manufacturer’s 
instructions. FAIRE DNA from both replicates was prepared as per the manufacturer’s 
recommendations (TruSeq DNA Sample Prep Kit; Illumina), and 50-bp reads were sequenced 
(HiSeq 2000; Illumina) at the University of North Carolina High-Throughput Sequencing 
Facility. Cells in a 96-well format were incubated for 16 h with compound or vehicle at a final 
concentration of 10 μM. After formaldehyde cross-linking, cells were sonicated in Lysis Buffer 
A. Input was collected from untreated cells in the first column of each plate, and FAIRE was 
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performed on remaining samples using columns (D5207; Zymo Research). Relative chromatin 
inhibition was determined by performing qPCR on FAIRE and input samples.  
 
Analysis of Standard FAIRE and HT-FAIRE. 
FAIRE data from seven cell lines (H1-hESC, HeLa, HepG2, NHEK, K562, GM12878, 
and HUVEC) were generated previously (77). For all signal-based analyses, one replicate was 
used for all cell lines except HUVEC, for which data from both replicates were used in parallel. 
Published sets of FAIRE sites were used in all cases. For HT-FAIRE, data from both replicates 
were combined, and one set of FAIRE sites was called using MACS2 (78) with a shift size set to 
100. For hierarchical clustering analyses, we computed normalized FAIRE signal in 500-bp 
nonoverlapping windows across the genome. Windows were first filtered for those with an 
average signal greater than 0.25 (581,514 windows remained) and that fell within an expected 
range (580,605 windows remained). Windows exhibiting a wide variation across samples (SD 
greater than 0.5; 9,711 windows remained) were then selected. Signal in these windows was then 
median-centered and hierarchically clustered using average linkage. ChIP-seq data for histone 
modifications and transcription factors, as well as DNase hypersensitivity, were generated 
previously (77). Repetitive element classes were as defined by RepeatMasker, and genomic 
redundancy was computed for 36- and 50-bp reads using PeakSeq (79). Motifs in clusters 1–3 
were identified using HOMER (80) using the 500-bp flanking sequence as background. Motifs 
were considered significant if they had a q-value equal to 0, they occurred in >20% of the target 
sequences, and had a greater than threefold enrichment in the target sequences relative to 
flanking sequences (background). Motifs in the same transcription factor family were merged for 
simplicity of presentation. 
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Detailed Description of High-Throughput FAIRE Screen 
The automated, high-throughput FAIRE screen was performed in a 96-well format. 
Compound and vehicle controls were used in the assay at a final concentration of 10 μM in 0.1% 
DMSO in cell culture media. Compounds were plated onto a 96-well V-bottom cell culture plate 
(651180; Greiner Bio-One), and EWS894 cells were added (Multidrop Titertek) at 1 × 105 cells 
per well in a 100-μL final volume of cell culture media (RPMI supplemented with 15% FBS). 
Cells were incubated with compound for 16 h at 37 °C and 5% CO2 and then harvested. 
Formaldehyde diluted in cell culture media to a final concentration of 1% per well was added 
(Multidrop Titertek). Plates were incubated for 5 min at 37 °C and 5% CO2, followed by addition 
of glycine to a final concentration of 125 mM and incubation at room temperature for 5 min. 
Plates were centrifuged for 5 min at 500 × g (5810R centrifuge; Eppendorf) to pellet the cells. 
Media were removed by quickly inverting the plate. Cells were washed once with PBS and 
pelleted. A Tecan Evo 200 was used for all subsequent liquid handling. Cells were suspended in 
50 μL of Lysis buffer A (57) and transferred to a 0.2-mL 96-raised well PCR plate (27-105; 
Genesee Scientific) for sonication. The plates were sealed with a 96-well silicone sealing mat 
(22-513; Genesee Scientific), and a pin lid was pushed through the seal (SL0096-P21-SS; 
Matrical Bioscience). Plates were sonicated (SonicMan; Matrical Bioscience) for 20 cycles for 
15 s at 60% power. Then, 700 U of RNase (2900142; 5 Prime) was added to each well and 
incubated for 5 min at room temperature. Untreated samples from the first column of the plate 
were removed and pooled for input DNA. The input sample was digested with 20 μg of 
proteinase K at 55 °C overnight and then purified by phenol-chloroform extraction. FAIRE was 
performed by transferring liquid from the remaining wells in columns 2–12 to a ZR-96 ChIP 
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DNA silica matrix clean and concentrator column (D5207; Zymo Research). The column was 
then washed according to the manufacturer’s instructions using a QiaVAC 96 (19504; Qiagen). 
DNA was eluted in a 100-μL Elution Buffer (Zymo Research). DNA was separated on a 1.5% 
agarose gel to confirm fragmentation. Ten microliters of the remaining input was diluted 1:1,000 
and added back to the plate containing the FAIRE DNA. Buffer alone was also added to the plate 
as a control for qPCR. Two microliters of each sample was transferred from the 96-well plate to 
a 384-well plate for use in qPCR. Input samples were diluted 1:1,000, and FAIRE samples were 
diluted 1:100 in water for comparison of standard and HT-FAIRE. Input samples were diluted 
1:1,000, and FAIRE samples (100-μL elution volume) were used undiluted for the HT-FAIRE 
screen. Two microliters of each diluted sample was subjected to quantification qPCR in duplicate 
on the ABI 7900HT using FastStart SYBR Green Master Mix ROX (Roche) in a 10-μL final 
volume. Primer sequences are listed in Table 2.3. Percent input was determined using the ΔCt 
method (76) . For the comparison of phenol-chloroform and column-based FAIRE methods, ΔCt 
values were normalized to a genomic region near the PRPF31 gene that is negative for FAIRE 
signal. For the FAIRE screen, relative chromatin inhibition was calculated using the following 
equation: (((ΔΔCtP1/ΔΔCtAURKAIP1) + (ΔΔCtP7/ΔΔCtAURKAIP1))/2), where P1 and P7 are 
EWSR1-FLI1–dependent open chromatin regions, AURKAIP1 is a region of chromatin that 
consistently has a positive FAIRE signal, and ΔΔCt is (FAIRE CtTREATED/Input 





Supplementary Table 3: Quantitative PCR primers used in this study.
Name Oligo Sequence
AURKAIP1 Forward (postive control) TATACCCGCAGGTCCAGAATCGTT
AURKAIP1 Reverse (positive control) AATAGCTCTAGACGCTTCCGCCTT
BC006361 Forward (negative control) TTCTCCAACTTTGGAAGCCCAGGA
BC006361 Reverse (negative control) TGTCTCCTTCTAGGCCCTCACAAT
P1 Forward (EWSR1-FLI1 binding) AAGGAAGGAAGGGAGGGACACATAC
P1 Reverse (EWSR1-FLI1 binding) CCTGTGAGTGTGACAGATTACTTGG
P7 Forward (EWSR1-FLI1 binding) GGGTGACAGAGTAAGATCCTGTCAGA

































Target 3 Forward GCATCAGGAAGCCTGGATCCATTA
Target 3 Reverse GTATATACCAACACCCTTCCCTG
Target 4 Forward AGATCCGGTTCAAATGGCAAGAGC
Target 4 Reverse GCACTCATCCTTAAGCCTCAACCA
Control 2 Forward CAAACTTCGGCTCACTTCGGCAAT
Control 2 Reverse AAGAAAGCCGAAACATGTCGCTCC
EWSR1-FLI1 mRNA Forward GCTATGGTCAACAAAGCAGCTATG
EWSR1-FLI1 mRNA Reverse TTGGCTAGGCGACTGCTGGT 
RPL27 mRNA Forward GACGCAAAGCTGTCATCGTG
RPL27 mRNA Reverse GCAGTTTCTGGAAGAACCAC




RNA was extracted (74134; Qiagen) followed by cDNA synthesis (Superscript III; 
Invitrogen). Ten microliters of qPCR reactions (SYBR Green Mastermix; Bio-Rad or Biotool) 
were performed according to the manufacturers’ instructions. qPCR for FAIRE and cDNA was 
performed (ViiA7 Real-Time PCR system; Applied Biosystems) and analyzed using the ΔΔCt 
method (76). 
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Chapter 3: UNC0621 is a novel small molecule inhibitor of chromatin accessibility in 
Ewing sarcoma 
3.1: Introduction 
In addition to HDAC inhibitors, the automated FAIRE screen led to the identification of 
many small molecule compounds that decreased chromatin accessibility at EWSR1-FLI1 binding 
sites. The majority of these compounds, indicative of the composition of the EpiG library, were 
designed as inhibitors towards specific proteins but possessed yet-to-be-determined biological 
function and targets. One such compound, UNC0621, appeared to be a particularly potent 
inhibitor of chromatin accessibility (Fig 3.1). This compound was intriguing because it is an 
analog of UNC0638, a well-characterized inhibitor of the G9a/GLP histone methyltransferases 
(51). UNC0638 was included in the EpiG library, but caused a negligible effect on chromatin 
accessibility in the screen. This led to supposition that UNC0621 was in fact acting on chromatin 
through an undetermined secondary target and mechanism.  
To begin to explore the mechanism of action of UNC0621 in Ewing sarcoma cells, we 
compared its function to that of the previously studied HDAC inhibitors. As we found HDACi 
decreased chromatin accessibility through a decrease in EWSR1-FLI1 protein levels, we asked 
whether UNC0621 caused the same effect. Upon analyzing EWSR1-FLI1 protein levels 
following treatment of EWS894 cells with UNC0621 for 16 hours, we observed no significant 
difference in proteins levels of treated cells relative to a vehicle control (Fig 3.2A-B). This 











Figure 3.1: Chromatin signature-based screen identified UNC0621 as an inhibitor of 
EWS-FLI-dependent chromatin accessibility. (A) log2 ratio of the relative chromatin 
inhibition values was plotted against the rank order of compounds from greatest relative 
decrease (top, left side of X-axis) to the greatest relative increase (top, right side of X-axis) 
in FAIRE signal following compound treatment.  The dashed lines indicate the significance 
cutoff of relative chromatin inhibition values greater or less than two standard deviations 
from the average FAIRE signal for vehicle-treated controls.  Thirty compounds that show 
the greatest decrease in FAIRE signal for each plate are magnified (bottom graph).  The bar 
representing UNC0621 is highlighted in black with an asterisk (*). (B) Standard FAIRE-
qPCR at 11 genomic loci known to be enriched by FAIRE in EWS894 cells following 16-hr 
treatment with 10 μM UNC0621. “Target” sites were dependent on the binding and 
presence of EWS-FLI1 for a positive FAIRE signal, whereas “Control” sites were not EWS-
FLI1-dependent.  Error bars represent the standard deviation of three biological replicates. 
(C) HT-FAIRE-qPCR at the same genomic regions used for the original screen was 
conducted following treatment of EWS894 cells for 16 hours with 3-fold dilutions of 
UNC0621 or a control compound in concentrations ranging from 1.11 to 0.01 μM.  Error 
bars represent the standard deviation of 4 replicates for UNC0621 and the standard error of 





Seeking to understand the effect of UNC0621 on Ewing sarcoma cells, we asked whether 
treatment with the compound affected cell viability. To measure cell viability we used WST-1, 
an assay that involves the conversion of WST-1 to formazan by NADH+ produced by respiring 
cells, resulting in a color change. A darker color, quantified by absorbance, indicates more 



































Fig 3.2: UNC0621 functions via a mechanism distinct from HDAC or G9a inhibitors. (a) 
EWS894 cells were treated with 10 μM UNC0621 for 16 hours, followed by western blotting 
with whole cell extract.  (b) EWSR1-FLI1 and tubulin bands were quantified (LiCor) and 
plotted as a ratio. (c) Cell viability was assayed using WST-1 reagent (Roche) and 
spectrophotometry. Background absorbance (620 nm) was subtracted from assay absorbance 
(450 nm) values. Relative cell viability is expressed as CompoundAbs450-620/DMSOAbs450-620. 
	 37	
titration of UNC0621, concentrations 10 μM to 0.156 μM, and performed a WST-1 assay 72 
hours after treatment to measure cell viability. Interestingly, we observed that treatment with 
UNC0621 caused a dose-dependent decrease in the cell viability of EWS894 cells, with an EC50 
of about 600 nM. Moreover, the published G9a inhibitor UNC0638 has a far less potent effect on 
cell viability, with an EC50 of about 3 uM. The potency of UNC0621 on decreasing both 
chromatin accessibility and cell viability suggested this compound was potentially targeting 
cancer-relevant epigenetic processes. 
 
3.2: Generation and testing of UNC0621 derivatives  
In order to study the mechanism of action of UNC0621, we needed a system to identify 
direct interactions with the compound. We desired a “handle” on the compound that could be 
attached to various moieties and used for compound interaction studies. Kyle Butler and Jian Jin 
(Mt. Sinai School of Medicine) generated compound derivatives possessing a short alkene linker. 
The resulting analogs, UNC4151 and UNC4152, possess the same structure as UNC0621 save 
for the addition of a short carbon linker and alkene (Fig 3.3A). The derivatives are distinguished 
by the location of the linker. Multiple derivatives were generated in order to determine the best 
location for the linker that would have the least impact on the function of the small molecule. 
To determine whether the alkene linker affected compound activity, we compared the 
function of the new analogs to that of the parent compound UNC0621. First, we examined how 
the compounds affect chromatin accessibility by treating EWS894 cells with varying doses of 
each compound for 16 hours followed by the FAIRE assay. As previously shown, UNC0621 
caused a marked and dose-dependent decrease in chromatin accessibility at EWSR1-FLI1 target 




































Fig 3.3: UNC0621 derivatives differ in their in biological activity. A) Structure of 
UNC0621 and derivatives UNC4151 and UNC4152. B) FAIRE-qPCR performed on 
EWS894 cells treated with  all 3 compounds, Relative chromatin inhibition score is a ratio 
of FAIRE signal at test regions (oncoprotein bound sites) and an unbound control. Error 
bars represent standard deviation of 5 technical replicates. C) Cell viability assay in 
EWS894 cells treated with UNC0621 and derivatives. Relative viability is plotted as 
absorbance relative to DMSO. Error bars represent standard deviation of 3 technical 
replicates. 
	 39	
Similarly, treatment with the UNC4151 analog caused a comparable decrease in 
chromatin accessibility at analyzed sites. Contrastingly, UNC4152 did not significantly affect 
chromatin accessibility relative to vehicle control. This indicates that the UNC4151 analog 
retains the chromatin modulating function of UNC0621, whereas this has been ablated in 
UNC4152. 
To further compare the activities of the analog compounds to the parent UNC0621, we 
examined their effect on cell viability. UNC0621 had previously been demonstrated to decrease 
proliferation of Ewing sarcoma cells as measured by WST-1. We treated EWS894 cells with a 2-
fold dose titration of all three compounds, from 10 μM to 0.156 μM, then measured cell viability 
by WST-1 72 hours after treatment. We observed that, as expected, cell viability decreased with 
increasing concentrations of UNC0621. UNC4151 treatment closely recapitulated UNC0621, 
exhibiting a similar effect on cell viability (Fig. 3.3C). However, UNC4152 exhibited an 
attenuated effect, with only the highest concentration (10 μM) resulting in a decrease in viability 
and the remaining concentrations causing no effect relative to vehicle control. Together with the 
FAIRE results, this suggests that UNC4151 functions similarly to UNC0621 whereas UNC4152 
demonstrates perturbed function. Therefore, we conclude that the location of the linker in 
UNC4151 has negligible impact on compound activity and can be used to study potential 
interactions of UNC0621. Additionally, the disrupted activity of UNC4152 gave the potential for 
this derivative to be used as an “inactive” control compound and help eliminate biologically 
irrevelant interactions in future studies.  
UNC4151, as well as “inactive” derivative UNC4152, were conjugated to NHS sepharose 
beads through the short carbon linker present in both compounds. The sepharose acts as a tether 
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that can be isolated in pull-down experiments, thereby allowing detection of factors interacting 
with the associated compounds.  
 
3.3: UNC0621 derivative compounds interact with nuclear proteins 
Having observed that UNC4151 possesses comparable biological activity to that of 
UNC0621, we then wanted to use this compound to study protein interactions of UNC0621 and 
identify potential molecular targets. Due to the initial discovery of UNC0621 as a chromatin-
modulating compound, we hypothesized that the most relevant targets were likely nuclear 
proteins. To determine interaction of UNC0621 with nuclear proteins, we used the “active” 
derivative UNC4151 conjugated to sepharose as a proxy to detect relevant UNC0621 
interactions. Additionally, we used regular NHS sepharose beads as a negative control and the 
“inactive derivative” UNC4152, also conjugated to sepharose, as a quasi-control probe with 
similar structure but disrupted activity. We hypothesized that nuclear proteins would be 
associated with bead-conjugated compounds, and that relevant interactions would exhibit greater 
association with UNC4151 than with UNC4152.  
To determine nuclear protein interactions with bead-conjugated compounds, we isolate 
nuclear proteins from Ewing sarcoma cells and incubated with sepharose beads alone or bead-
conjugated UNC4151 or UNC4152. Samples were then allowed to drip through the column, with 
interacting proteins remaining bound to beads. Bound proteins were eluted off with soluble 
UNC0621 followed by SDS-PAGE silver stain analysis. For both EWS502 and EWS894 cells, 
we observed peptides across a wide range of molecular weights were pulled down abundantly 




































































































































































Fig 3.4: Bead-conjugated UNC0621 derivatives interact with histones and nuclear 
proteins. A) Silver stain analysis of nuclear protein pull-down with bead-conjugated 
derivatives. B) Silver stain analysis of proteins present in the flow through from nuclear pull-
downs (“0.03% unbound”) and proteins that remained associated with sepharose following 
pull-downs (“4% beads”). C) Nuclear protein pull-down samples show presence of histone 
H3 by western blot. D) Nucleosome pull-downs with bead-conjugated compounds show 
presence of histone H3 by western blot. Nucleosomes were isolated from HEK293T cells. 
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associated with the empty NHS sepharose beads, they were far less abundant, indicating that 
background binding to just the sepharose was reasonably low. Interestingly, although many 
peptides were associated with the inactive UNC4152, they were less abundant than the 
interactions with UNC4151. Because the binding reactions were controlled for initial protein 
concentration and small molecule molarity, it can be assumed that the observed difference in 
abundance is due to a difference in binding efficiency of the compounds. This agrees with our 
hypothesis that interacting proteins would associate more abundantly with UNC4151. Therefore, 
these data suggest that while the inactive derivative UNC4152 does interact with nuclear 
proteins, it does so with lower efficacy than UNC4151. This difference in interaction efficiency 
could potentially explain the severely perturbed, though not absent, biological function of 
UNC4152.  
 We wanted to determine whether there were nuclear proteins that were not captured in 
the compound pull-downs. To address this, we analyzed the portion of the lysate that had flowed 
through the chromatography column, and therefore had not bound to the sepharose. We analyzed 
the flow-through from all pull-downs by silver stain analysis and observed in all samples a high 
abundance of proteins across the entire range of molecular weights that had not bound to the 
sepharose. Surprisingly, although the eluted fractions varied, the unbound fraction of UNC4151 
and UNC4152 pull-downs appeared equally as concentrated as that of the sepharose beads 
control.  
Additionally, to address the efficacy of the elution with UNC0621, we asked what 
proteins were still associated with the sepharose beads following the protein pull-down.. We 
observed many proteins were still associated with the beads conjugated to UNC4151 and 
UNC4152, though the latter exhibited decreased overall associations. This indicated that elution 
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with free UNC0621, though somewhat effective, failed to liberate many proteins associated with 
bead-conjugated small molecules.  
In analyzing the pattern of UNC0621 derivative-interacting proteins, we noticed the most 
abundant species was at approximately 16 kD. We hypothesized that these could be histones, 
with the rationale that histones have the same observed molecular weight and are very abundant 
within the nucleus. To address this, I performed a western blot to detect total levels of histone H3 
in nuclear pull-down lysates. I observed that H3 was undetectable in the NHS sepharose negative 
control but was present in nuclear pull-downs from UNC4151 and UNC4152. Additionally, H3 
levels are lower in the UNC4152 pull-down than with UNC4151, which is consistent with our 
previous observation that the UNC4152 pull-down has overall lower protein abundance than the 
pull-down with UNC4152. Therefore, UNC0621 interacts with histone H3 and this association is 
stronger with the active derivative compound than the inactive compound. In addition, the pull-
downs were shown to be highly enriched for all histones by mass spectrometry (Amber Mosley, 
Indiana University).  
Although histones were highly enriched by mass spectrometry, it could not be determined 
whether these interactions were in the context of a protein complex or more direct. To 
understand how UNC0621 engages histones, we asked whether UNC0621 could bind to 
nucleosomes. We generated a crude solution of mononucleosomes by isolating intact nuclei and 
treating with micrococcal nuclease (MNase). MNase is an endonuclease that digests the linker 
DNA between individual nucleosomes, thereby fragmenting chromatin into regular nucleosomal 
arrays. By using a high concentration of MNase, we are able to yield primarily 
mononucleosomes. We incubated the mononucleosomes with sepharose-conjugated UNC4151 
and UNC4152, then harvested the sepharose beads and boiled to liberate bound proteins. Isolated 
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proteins were separated by SDS-PAGE and analyzed by western blot to detect total levels of 
histone H3. We detected high signal for H3 in nucleosome pull-downs for UNC4151 and 
UNC4152, and there was no detectable H3 isolated with the empty sepharose beads alone. 
Moreover, we again observed lower levels of H3 associated with inactive derivative UNC4152 
than with UNC4151, further indicating that the former compound has decreased binding efficacy 
relative to the latter.  
Derivatives of UNC0621 conjugated to sepharose beads have demonstrated great 
potential in detecting compound-specific interactions. We have shown that UNC0621 derivatives 
interact with a wide range of nuclear proteins, and these interactions are enriched for histone 
proteins. However, the unbound fractions corresponding to the nuclear pull-downs were 
concentrated, suggesting that the binding capacity of the sepharose-conjugated was exceeded and 
many proteins were excluded. Additionally, following elution with UNC0621 to remove bound 
proteins, many proteins remained bound to the sepharose. It is possible that this elution was 
lacking in efficacy. Therefore, development of a more effective elution strategy would likely 
increase the protein yield and assist in identifying additional relevant interactions.  
In subsequent nucleosome pull-down experiments, we found that sepharose-conjugated 
UNC0621 derivatives pull-down histones, providing further evidence for engagement with 
nucleosomes by UNC0621. However, while the lysate was enriched for nucleosomes, other 
nuclear proteins are present. It must still be determined whether UNC0621 directly interacts with 
nucleosome particle directly or indirectly through other chromatin-associated proteins.  
Elutes of proteins associated with the active derivative UNC4151 are more concentrated 
than those associated with the inactive derivative UNC4152, indicating that the inactive 
compound has decreased interaction efficiency. Since UNC4152 does still bind protein, it is 
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plausible that the decreased biological activity of this derivative is due to attenuated interactions 
rather than a complete loss of function. However, the difference in binding between UNC4151 
and UNC4152 can be potentially useful in determining biologically relevant interactions of 
UNC0621. 
 
3.4: UNC0621 derivatives bind to fragmented fixed chromatin with high affinity 
UNC0621 was identified as a chemical modulator of chromatin accessibility in Ewing 
sarcoma cells. We examined protein interactions of UNC0621 by performing nuclear protein 
compound pull-downs followed by silver stain and mass spectrometry analysis, and we identified 
histones associated abundantly with UNC0621 derivatives. Taking together the biological effect 
of UNC0621 on chromatin and its apparent interaction with histones, we hypothesized that 
UNC0621 directly binds to chromatin. To explore this hypothesis, our goal was to perform a 
chromatin pull-down with a tagged derivative of UNC0621 and determine the abundance of 
associated chromatin, the affinity of the interactions, and genome-wide localization (ref).  
 First, we asked whether we could detect an interaction between chromatin and UNC0621. 
I developed a chromatin pull-down protocol adapted from protocols for ChIP, Chem-seq, and 
Chem-ChIP (83,84). All methods have comparable instructions on formaldehyde fixation of cells 
and chromatin fragmentation, with subsequent divergence on pulling down chromatin with an 
antibody or small molecule compound. For initial experiments, we utilized UNC0621 
derivatives, UNC4151 and UNC4152, conjugated to sepharose beads. Sepharose-conjugated 
compounds were incubated with fragmented crosslinked chromatin from EWS894 to determine 
the compounds’ association with chromatin. We then quantified samples to determine the 
amount of chromatin associated with compounds. We found that chromatin associated with 
bead-conjugated derivatives,  and when compared to a parallel processed input control, saw that 
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each pull-down contained 5-10% of the starting material used for each pull-down reaction (Fig 
3.5A). Moreover, chromatin pull-downs performed with NHS sepharose beads as a negative 
control only represented ~0.1% of the input chromatin amount. This demonstrates that 
background association of chromatin with sepharose alone is low, indicating that chromatin 
interacts selectively with sepharose-conjugated UNC0621 derivative compounds.  
 Possessing evidence that UNC0621 does in fact interact with chromatin, we desired to 
use a derivative compound we believed would increase detection specificity. We utilized a 
biotinylated UNC0621 derivative, KB-13-60, that can be pulled out with magnetic beads coated 
with streptavidin. The use of magnetic beads rather than sepharose allows for a more streamlined 
isolation process while the strength of the biotin-streptavidin interaction maintains efficiency. 
Moreover, we wanted to determine whether the amount of associated chromatin is proportional 
to the amount of compound used for a pull-down. The listed binding capacity of the streptavidin 
magnetic beads is 1.1-1.7 nmol of biotin per mg of magnetic beads, and the beads are at a 
concentration of 10 mg/ml. With the assumption that the binding capacity would only be slightly 
lower for a biotinylated small molecule compound, we calculated the binding capacity of 0.5 mg 
streptavidin beads (equal to 50 uL) to be approximately 0.5 nmol of KB-13-60. To effectively 
vary the concentration of KB-13-60, we used a maximum of 0.5 nmol KB-13-60 and kept beads 
constant at 0.5 mg. Avoiding saturation of the beads would ensure the accuracy in the variation 
of each concentration of KB-13-60.  
To test the utility of KB-13-60 for detecting chromatin interactions, we incubated varying 
concentrations of the compound with fragmented chromatin followed by addition of streptavidin-
coated magnetic beads to pull out KB-13-60 in complex with associated chromatin. We 



































































































































Fig 3.5: UNC0621 compound derivatives interact with fragmented chromatin. A) 
Chromatin pull-down using sepharose-conjugated compound derivatives. Values plotted as 
a percentage of an equivalent volume of not used for a pull-down (“input”). B) 
Representative chromatin pull-down using varying amounts of biotinylated derivative KB-
13-60. Graph depicts total yield (ng) for each pull-down. C).  Chromatin pull-down with  
0.125 nmol KB-13-60 following pre-incubation of chromatin with either 5 nmol UNC0621 
or DMSO. Error bars indicate standard deviation between 3 technical replicates. D) 
Representative experiment showing chromatin pull-down with KB-13-60 followed by 
elution with either UNC0621 or DMSO. DNA in the supernatant (“elute”) and what 
remained associated with streptavidin beads (“bound”) was quantified and plotted as a 
percentage of input.  
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proportional to the amount of KB-13-60 used for the pull-down, with the DNA yield dropping 
roughly two-fold with each two-fold decrease in compound concentration. This is further 
evidence of the specific interaction of chromatin with KB-13-60, and demonstrates quantitative 
nature of the interaction at compound concentrations below the binding capacity of the 
streptavidin beads. While the bead-conjugated compounds and KB-13-60 interact with similar 
efficacy, we can more easily and accurately titrate the amount of KB-13-60. Therefore, we chose 
to use KB-13-60 for subsequent chromatin interaction experiments. 
Next, we wanted to understand the nature and specificity of the UNC0621-chromatin 
interaction. I hypothesized that if UNC0621 is indeed binding to chromatin, competition with 
free UNC0621 would occlude binding of KB-13-60 to chromatin. Since the interaction studies 
require the use of UNC0621 derivative compounds, competition experiments will permit 
interrogation of the binding properties of original UNC0621. To examine the ability of KB-13-60 
to engage chromatin in the presence of UNC0621, I first incubated chromatin with UNC0621 or 
DMSO as a control then performed a chromatin pull-down with KB-13-60. Upon quantifying 
isolated chromatin, I observed that less chromatin was pulled down from reactions pre-incubated 
with UNC0621 relative to those pre-incubated with DMSO. DMSO-incubated pull-downs 
UNC0621 KB-13-60
Fig 3.6: Structures of UNC0621 and its biotinylated derivative KB-13-60. 
Synthesized by Kyle Butler and Jian Jin (Mt. Sinai School of Medicine) 
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averaged ~7% of input DNA, UNC0621-incubated samples averaged ~5% of input. While this 
difference was consistent, it represents only ~33% difference, indicating that KB-13-60 is still 
able to effectively bind to chromatin in the presence of UNC0621.  
We also wanted to determine the ability of UNC0621 to compete off chromatin already 
bound to KB-13-60. To address this, we performed a chromatin pull-down with KB-13-60, then 
incubated the beads with wash buffer containing either UNC0621 or DMSO for 24 hours. 
Effective competition by UNC0621 would result in chromatin being present in the wash buffer 
rather than bound to KB-13-60 on the streptavidin beads. We quantified the DNA remaining on 
the beads as well as in the supernatant. In both UNC0621 and DMSO elution conditions, DNA in 
the supernatant was barely quantifiable and chromatin remained associated with streptavidin 
beads. Although UNC0621 is able to partially occlude binding of KB-13-60 to chromatin, under 
conditions tested UNC0621 cannot successfully compete for binding once KB-13-60 was already 
bound to chromatin. This suggests that KB-13-60 possesses the same binding targets as 
UNC0621, but KB-13-60 is able to bind chromatin more efficiently.  
To explore the possibility of UNC0621 derivatives binding to the DNA component of 
chromatin rather that through a protein target as hypothesized, I performed a chromatin pull-
down with KB-13-60 in the presence or absence of proteinase K. In the presence of proteinase K, 
interaction between chromatin and KB-13-60 is ablated (Fig 3.7A-B). This supports our 
hypothesis that UNC0621 derivatives associate with chromatin through a protein intermediate.  
Chromatin pull-downs with KB-13-60 show that the compound has a high affinity for 
chromatin, as associated chromatin is not eluted effectively with UNC0621. To better understand 
the affinity of the compound for chromatin, we asked whether elution of compound-bound 
chromatin was affected by sodium chloride (NaCl) concentration. NaCl is known to disrupt 
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macromolecular interactions at high concentrations, particularly those with proteins. We 
hypothesized that increasing the concentration of NaCl would disrupt the protein target(s) of 
UNC0621 and consequently cause dissociation of chromatin from the compound. To assess the 
effect of NaCl concentration on the UNC0621-chromatin interaction, we performed a chromatin 
pull-down with KB-13-60 and incubated the compound-bead-chromatin complex with varying 
concentrations of NaCl. NaCl concentration ranged from 300 mM, the original concentration of 
the reaction buffer, up to 2 M. We incubated the beads with lowest concentration NaCl wash 
buffer, then removed a fraction of the bead solution and saved the supernatant as the “elution” 
for that NaCl concentration. Beads were subsequently incubated with the next highest 
concentration of NaCl, and another fraction was removed and supernatant retained. The process 
was repeated for each NaCl concentration in ascending order, with the same fraction of the 
starting amount removed after each incubation. Using this method, the quantity of each elution 
could be directly compared to each other. Moreover, each subsequent incubation is done with the 
same chromatin pull-down, allowing us to examine the relative contribution of each NaCl 
concentration on elution of KB-13-60-bound chromatin.  
We quantified the eluted chromatin at each tested NaCl concentration as well as the 
chromatin that remained on the beads following all washes. A standard chromatin pull-down was 
prepared in parallel for comparison. 300 mM and 500 mM NaCl did not effectively elute 
chromatin off of beads, with quantified amounts in eluate lower than even the background 
control (Fig 3.7C). Elutions at 750 mM, 1 M, and 2 M NaCl exhibited higher concentrations of 
chromatin, at 1-2% of input quantity. Surprisingly, a significant amount of chromatin remained 
associated with streptavidin beads, about 5% of input relative to the ~4% that was eluted. 
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Fig 3.7: Cross-linking increases the affinity of KB-13-60 for chromatin. A) Pull-down 
with chromatin subjected to proteinase K treatment (ProtK+) prior to pull-down. A standard 
pull-down and negative control were performed in parallel and plotted for comparison. B) 
Representative experiment with proteinase K treatment for chromatin at varying time points 
prior to pull-down. Treatments were started at various times, each with a matched control, and 
all were stopped at the same time. Chromatin pull-downs performed in parallel. C) and D) 
Chromatin pull-down with elutions containing various concentrations of NaCl, with 
chromatin from either standard fixed EWS894 cells (C) or unfixed cells (D). Graphed is the 
chromatin quantified in each elution and remaining on the beads following all washes (“salt 
washed beads”). A representative pull-down is shown for each condition. Values on all graphs 
are plotted relative to an input control.  
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even after being washed with up to 2 M NaCl. This indicates that the affinity between KB-13-60 
and chromatin is great enough to withstand high concentrations of NaCl.  
We found it striking that 2 M NaCl was not sufficient to dissociate chromatin from KB-
13-60. The apparent high affinity of this interaction led us to consider additional variables that 
were at play, in particular the inclusion of formaldehyde. Formaldehyde is included in the 
standard chromatin preparation and stabilizes protein interactions through cross-linking. Since 
UNC0621 appears to engage chromatin through a protein target, we asked whether the utilization 
of formaldehyde influences engagement of KB-13-60 with chromatin. To address this, I 
performed a KB-13-60 chromatin pull-down followed by salt elutions, as previously described, 
using chromatin from unfixed cells. Omitting the addition of formaldehyde, I isolated and 
fragmented chromatin from EWS894 cells and performed a chromatin pull-down with KB-13-
60. Following binding of the compound to chromatin, I incubated the streptavidin beads with 
various concentrations of NaCl to elute bound chromatin. I then quantified the DNA present 
eluted at each concentration of NaCl and compared to the corresponding values obtained from 
fixed chromatin. I observed that the bulk of unfixed chromatin dissociates from KB-13-60 at 300 
nM and 500 nM NaCl, with negligible amounts eluted at higher NaCl concentrations and 
remaining on the streptavidin beads after all washes (Fig 3.7D). This is in stark contrast to the 
quantities obtained with crosslinked chromatin, for which 300-500 nM NaCl liberates only 
negligible amounts of chromatin. These data suggest that crosslinking cells does in fact alter the 
affinity of the biotinylated KB-13-60 for chromatin. More specifically, KB-13-60 interaction 
with fixed chromatin is much more stable than with unfixed, and can withstand high 
concentrations of NaCl. Interestingly, the NaCl range that causes dissociation of KB-13-60 from 
unfixed chromatin is comparable to that at which the histone octamer dissociates (85). Therefore, 
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these findings are consistent with the observation that UNC0621 might bind histones or other 
nucleosome-bound proteins directly. 
 
3.5: Discussion 
Our studies with the tagged derivative compounds of UNC0621 have yielded valuable 
insights into the interactions of this compound with chromatin. We have shown that sepharose-
conjugated compounds interact with nuclear proteins, in particular with histones. Because 
histones are a rather unconventional target, it is likely that there are other relevant protein targets 
of this compound. However, our elution by competition with equal molar UNC0621 was not the 
most effective, and therefore potentially interesting interactions could have been lost. Moving 
forward we are working on optimizing elution strategies and protein isolation approaches. The 
interactions of UNC0621 with histones and other proteins are being pursued in ongoing 
experiments. 
Additionally, I have showed that biotinylated derivative compound KB-13-60 has high 
affinity for fixed chromatin and that this interaction is disrupted by competition with UNC0621. 
Importantly, I also showed that formaldehyde fixation increases the affinity of KB-13-60 for 
chromatin, stabilizing this interaction to the point of withstanding NaCl concentrations up to 2 
M, which is exquisitely resistant. Histone proteins, due to their abundance throughout chromatin, 
would be highly crosslinked by formaldehyde. Therefore, if histones or histone-associated 
proteins are in fact a target of UNC0621, this could provide a potential explanation for the 
resistance of the KB-13-60-chromatin interaction to extremely high concentrations of NaCl. 
Formaldehyde fixation, although standard in ChIP/Chem-ChIP protocols, has emerged a major 
variable that influences our interpretation of how UNC0621 derivative compounds interact with 
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chromatin. While we now have an increased understanding of how KB-13-60 interacts with 
crosslinked chromatin, we now aim to perform interaction experiments using unfixed chromatin 
to eliminate the variable of formaldehyde. Another goal is to capture in vivo chromatin 
interactions using a compound derivative that, following treatment can be conjugated to biotin 
using click chemistry. This approach would be necessary as KB-13-60 does not appear to be cell 
permeable. Pilot experiments for these proposed methods are currently underway. Ultimately, 
these approaches will allow us to interrogate the interaction of UNC0621 derivative compounds 
with chromatin in a more native, biologically relevant context.  
 
3.6: Methods 
Standard FAIRE quantitative PCR 
Cells were treated with 1% formaldehyde followed by inactivation with 125 mM glycine. 
Cells were resuspended in 2 ml of FAIRE lysis buffer (10 mM Tris-HCl pH 8, 2% Triton X-100, 
1% SDS, 100 mM NaCl, 1 mM EDTA) and sonicated (Misonix Sonicator® 3000). Lysates were 
then subjected to organic extraction using phenol-chloroform to isolate nucleosome-depleted 
chromatin. Chromatin fragments were incubated with RNaseA for 30 min at 37 °C, proteinase K 
for 1 hour at 55 °C, followed by overnight crosslink reversal at 65 °C. FAIRE DNA samples 
were purified (Zymo DNA Clean & Concentrate columns, #11-379). Input control DNA was 
treated with RNaseA and proteinaseK  prior to organic extraction. 
qPCR reagents were combined in a 384-well plate in 10 μL reactions containing 5 μL of 2X 
iTaq™ Universal SYBR® Green Supermix (Bio-Rad), 3 μL of 1 μM primer pair mix, 1 μL of 
water, and 1 μL diluted DNA. qPCR was performed using ViiA™ 7 Real-Time PCR system 
(Applied Biosystems) and each region was analyzed using the ΔCt method, calculating the 
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FAIRE DNA quantification relative to the corresponding input control. The effect of UNC0621 
treatment on each region was determined by ΔCtUNC0621-ΔCtDMSO. 
 
Western blots 
Proteins were extracted using RIPA lysis and separated by SDS-PAGE (Bio-Rad 
AnyKD™ SDS-PAGE gel, cat. No. 456-9035) then transferred onto nitrocellulose. Proteins were 
detected using fluorescent secondary antibodies, and quantified (LiCor). Antibodies as follows: 
α-Fli antibody (C-19, Santa Cruz sc-356, 1:1000), tubulin (Sigma T9026, 1:20,000), and histone 
H3 (from Strahl BD, 1:1000) 
 
Nuclear protein pull-down with sepharose bead-conjugated small molecules 
Nuclear proteins were isolated from EWS502 and EWS894 cells by cell lysis using 
Nuclei prep buffer to release intact nuclei followed by nuclei lysis. Nuclei were treated with 
Benzonase, a promiscuous exonuclease, to digest DNA and RNA, then ultra-centrifuged to 
isolate nuclear proteins. 50 uL Bead-conjugated UNC4151 and UNC4152, and NHS beads alone, 
were equilibrated with wash buffer in chromatography columns. Nuclear lysates were then 
incubated overnight in chromatography columns containing compounds. Samples were then 
allowed to drip through the column, with interacting proteins remaining bound to beads. Bound 
proteins were eluted off with soluble UNC0621 to compete off specific interactions. Elutions and 





Nucleosome pulldown with sepharose bead-conjugated small molecules 
 Nucleosomes were prepared according to protocol adapted from Ruthenberg et al (86). 
Sepharose-conjugated compounds were diluted 1:10 in NHS beads, and 30 uL of this dilution 
was added to micro-centrifuge tubes and washed thrice with protein binding buffer (PBB) + 
0.5% BSA to block beads. Prepared nucleosomes were added to micro-centrifuge tubes 
containing washed beads and rotate at 4C overnight. Compound-associated protein was collected 
by washing beads with PBB followed by resuspension of beads in 60 uL 2x SDS loading buffer. 
Sepharose beads were then boiled for 5 min to collect compound-associated proteins, which were 
then separated by SDS-PAGE and analyzed by western blot using antibody against histone H3. 
 
Chromatin pull-downs with biotinylated KB-13-60 
Chromatin was isolated from EWS894 cells and incubated with 0.125 nmol KB-13-60 in 
a 200 uL reaction volume for 2 hrs. MyOne T1 streptavidin-coated magnetic beads were added 
to reactions and incubated for 30 min. Bead-chromatin-compound complexes were then washed, 
then digested with RNaseA and proteinase K and boiled to reverse crosslinks and liberate 
compound associated chromatin. For input control, same volume of sonicated material used for 
pull-downs was immediate treated and RNaseA, proteinase K, and reversed crosslinks. Negative 
control reactions contained streptavidin beads with DMSO alone (no biotin).
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Chapter 4: UNC0621 inhibits proliferation and oncogenic growth in Ewing sarcoma 
4.1: Introduction 
Ewing sarcoma cells exhibit aberrantly accessible chromatin at loci bound by the 
EWSR1-FLI1 oncoprotein. Accessible chromatin at these regions is likely necessary for 
EWSR1-FLI1 to activate an oncogenic transcriptional network. We identified UNC0621 as a 
modulator of chromatin accessibility in Ewing sarcoma cells and found treatment with this 
compound decreases chromatin accessibility at oncoprotein-bound loci. Because of the probable 
role of these regions in oncogenic growth, we sought to interrogate the effect of UNC0621 on the 
cell biology of Ewing sarcoma cells.  
 
4.2: UNC0621 decreases viability of Ewing sarcoma cells 
I previously observed that UNC0621 decreases cell proliferation of EWS894 cells (Fig 
3.1). To explore whether this effect could be cell-type specific, I asked whether other cell lines of 
the same cancer type were similarly affected. I treated two additional Ewing sarcoma cell lines, 
EWS502 and A673, with various concentrations of UNC0621, ranging from 10 μM to 0.15625 
μM. I then assayed cell viability 72 hours after treatment using a WST-1 colorimetric assay. As 
in EWS894 cells, treatment with UNC0621 resulted in a dose-dependent decrease in cell 
viability in EWS502 and A673 cell lines, demonstrating the sensitivity of multiple Ewing 
sarcoma cell lines to UNC0621 (Fig 4.1A).  
I also wanted to determine how non-Ewing sarcoma cells responded to UNC0621. To 
determine this, I treated several additional cell lines with the same previously used 
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concentrations of UNC0621 and assayed cell viability using the same method. Relative to the 
Ewing sarcoma cells, many cell lines showed decreased sensitivity to UNC0621, including two 
renal cell carcinoma (UMRC2, 786-O), one primary renal (RPTEC) and a primary endotheilal 
(HUVEC) cell lines (Fig 4.1B-C). Therefore, Ewing sarcoma cells are exquisitely sensitive to 
UNC0621 treatment.  
Having observed the effect of UNC0621 across many doses, I also wanted to determine 
the how the compound affects cell viability over time. I treated EWS894 cells in a 96-well plate 
with 10 μM UNC0621 as assayed viability daily over the course of 6 days. Additionally, I 
assayed DMSO-treated cells at the same time points as a control. While cells treated with 
DMSO, showed an expected regular increase in absorbance over time, indicative of increasing 
cell number, those treated with UNC0621 exhibited a decline in absorbance values over time, 
indicating a decrease in cell viability (Fig 4.1D).  
I then tested whether the effects of UNC0621 persisted after withdrawal of the compound. 
Following exposure to UNC0621 (or control treatment) for three days, identical numbers of 
viable cells were placed in growth medium lacking compound and counted daily.  UNC0621 
exposure delayed the re-initiation of proliferation by approximately two days (Fig 4.1E). These 
data indicate that a fraction of EWS894 cells remain viable despite UNC0621 treatment and that 
treatment results in a persistent but reversible effect on proliferation.  
Finally, we tested the influence of UNC0621 on anchorage-independent growth, a 
characteristic feature of cancer cells.  Colony formation in soft agar was inhibited at 200 and 400 









Figure 4.1: UNC0621 affects proliferation, viability and transformation of Ewing sarcoma 
cells. Dose-dependent effect of UNC0621 on the viability of (a) Ewing Sarcoma cell lines, (b) 
renal cell carcinoma cell lines, and (c) human primary cells. Cell viability was assayed using 
WST-1 reagent (Roche) and spectrophotometry. Background absorbance (620 nm) was 
subtracted from assay absorbance (450 nm) values. Relative cell viability is expressed as 
UNC0621Abs450-620/DMSOAbs450-620.  Error bars represent standard deviation of three biological 
replicates. (d) Cells were cultured in the presence of 10 μM UNC0621 or 0.1% DMSO for six 
days, and viability was assessed daily using WST-1 reagent and spectrophotometry. Values are 
background corrected as above. Error bars represent standard deviation of three biological 
replicates.  (e) Cells were grown in the presence of 10 μM UNC0621 or 0.1% DMSO for 3 
days. Equal numbers of viable cells were then re-plated in the growth medium in the absence of 
compound and counted each day for 6 days. Error bars represent standard deviation of triplicate 
cell counts. (f) Effect of UNC0621 on anchorage-independent growth of Ewing Sarcoma cells. 
EWS894 cells were plated in agar-containing growth media containing UNC0621 or DMSO 
and incubated for 15 days. Fresh media containing UNC0621 was overlayed and changed every 
5 days. Colony formation was assessed on day 15 by MTT assay. (g) EWS894 soft agar colony 
counts. Error bars represent standard deviation of three biological replicates. 
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formation had minimal effect on viability in short-term culture (Fig 4.1F-G).  Taken together, 
these data demonstrate that UNC0621 has a potent effect on cell viability, proliferation, and 
transformation in Ewing sarcoma cells. 
While metabolic assays such as WST-1 and MTT correlate with the number of live cells, 
they do not distinguish between a decrease in cell proliferation or an increase in cell death. Due 
the observation that cells treated with UNC0621 for 3 days continue to proliferate following 
removal of the compound, I hypothesized that, under the same treatment conditions, UNC0621 
does not induce apoptosis. To test this, I measured the apoptotic population of UNC0621-treated 
EWS894 cells by annexin V staining. Annexin V binds to exposed phosphatidylserine following 
the inversion of the cell membrane during the early stages of apoptosis. Following staining, I 
analyzed treated cells by flow cytometry to detect the apoptotic, annexin V cell population. I 
observed robust annexin V signal in cells that had been treated with staruosporine treatment as a 
positive control. Interestingly, I observed that after 72 hours of treatment with 10 μM UNC0621, 
there was no significant difference in the apoptotic population when compared to cells treated 
DMSO (Fig 4.2). It should be noted that under these treatment conditions, UNC0621 causes a 
decrease in cell viability as previously measured by WST-1. Therefore, these data suggest that 
UNC0621 does not affect cell viability through induction of apoptosis.  
 
4.3: UNC0621 inhibits cell cycle progression of Ewing sarcoma cells 
As UNC0621 apoptosis did not seem to decrease cell viability through induction of 
apoptosis, I explored cell cycle arrest as a possible mechanism. If UNC0621 does in fact halt cell 
cycle progression, then one would expect to observe a lack of cell divisions over time. To 
directly measure cell division in the presence or absence of UNC0621, I utilized 
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carboxyfluorescein succinimidyl ester (CFSE) cell staining dye. CFSE is a non-toxic fluorescent 
dye that covalently binds to intracellular lysine residues and is diluted among daughter cells 
following cell division. As a result, the fluorescent signal in each cell decreases in intensity as a 





DMSO 10 μM UNC0621 1 μM Staurosporine
Fig 4.2: UNC0621 does not induce apoptosis in EWS894 cells. A) Cells were stained 
with annexin V and propidium iodide (PI) after 3 days of treatment, then analyzed by flow 
cytometry. PI signal is plotted on the y-axis, and annexin V signal on the x-axis. 
Staurosporine was used as a positive control for the induction of apoptosis. B) 
Quantification of the apoptotic Annexin V-positive and PI-positive population (upper right 
quadrant in A). 
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To determine whether UNC0621 halts cell division, I labeled EWS502 cells with CFSE 
then divided the labeled cells and treated with UNC0621 or DMSO, with three equal fractions 
per treatment. I then harvested and fixed a fraction for each treatment condition at 24, 48, or 72 
hours following treatment. Additionally, I fixed an equivalent number of untreated cells 
immediately after staining in order to capture the initial CFSE signal for reference. Following 
fixation, I quantified CFSE signal in all samples by flow cytometry (Fig 4.3). Cells harvested 
immediately after staining display high CFSE signal, which is expected as these cells have not 
divided. Of note, relative to the reference sample, cells treated with DMSO for 24 hours display 
lower average CFSE signal, indicating progression of cell proliferation. 48 hr DMSO-treated 
cells exhibit a further decrease in fluorescence, and even lower at 72 hr. These data show that 
CFSE-labeled cells continue to proliferate in the presence of DMSO as expected. Notably, there 
is a wide distribution of signal within a single sample, indicating variation in staining likely due 
to heterogeneity in cell size within the population. In addition, while fluorescence intensity 
decreases overtime, it does not decrease exactly by half relative to the subsequent time point. 
This is likely also due to heterogeneity in proliferation within the cell population and imprecise 
doubling after each 24 hr period. 
Upon observing the expected pattern of division among EWS502 cells treated with 
DMSO, I then compared CFSE-labeled cells treated with UNC0621 (Fig 4.3). 24 hr treatment 
with UNC0621 results in decreased fluorescence relative to the reference sample, suggesting 
active proliferation comparable to 24 hr DMSO-treated cells. Interestingly, fluorescence is 
further diluted in 48 hr UNC0621-treated cells, but this decrease is attenuated in comparison to 




Moreover, there is no change in CFSE signal between 48 and 72 hr UNC0621-treated cells. 
These data suggest that while cells are initially able to divide in the presence of UNC0621, 
proliferation ultimately slows after two days.  
  
4.4: UNC0621 induces a G0/G1 cell cycle arrest in Ewing sarcoma cells 
With quantitative evidence that UNC0621 disrupts cell proliferation, I then sought to 
determine whether this was due to a cell cycle arrest. To observe the different phases of the cell 
cycle, I utilized cell staining with propidium iodide followed by flow cytometric analysis. 
Propidium iodide (PI) is a fluorescent compound that intercalates with DNA, allowing for 
detection of total DNA content by flow cytometry. Cells in a particular stage of the cell cycle can 
















































Fig 4.3: UNC0621 inhibits cell division of Ewing sarcoma cells. EWS502 cells were 
stained with CFSE dye and treated with DMSO (left) or 5 uM UNC0621 (right) for 1, 2 or 3 
days. Cells were harvested, fixed, and analyzed by flow cytometry. Both treatment 
























































































































DMSO day 1 
DMSO day 2 
UNC0621 day 1 








G1 S G2 
DMSO 
UNC0621 0.625 µM 
UNC0621 1.25 µM 
UNC0621 2.5 µM 














Fig 4.4: UNC0621 causes Ewing sarcoma cells to arrest in G0/G1 of the cell cycle. A) 
EWS502 cells were treated with 5 uM UNC0621 or DMSO for the indicated periods, then 
stained with propdium iodide. PI signal was measured by flow cytometry. B) EWS502 cells 
were treated as indicated for 72 hours, followed by PI staining. All histograms display PI 
signal on the x-axis and event counts on the y-axis. Graphs represent proportions of 
population in each stage of the cell cycle estimated for both experiments.  
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represents the 2N DNA content population is indicative the cells that were G0/G1 phase of the 
cell cycle at the time of fixation. Cells in G2/M have a DNA content of 4N and appear as a peak 
with double the PI signal of the 2N peak. S-phase cells have an intermediate DNA content and 
therefore appear as a continuous population between the 2N and 4N peaks. 
To interrogate the effect of UNC0621 on cell cycle progression, I treated EWS502 cells 
with 5 μM UNC0621 or DMSO for 24 or 48 hours, then stained cells with propidium iodide and 
analyzed by flow cytometry. In a typical asynchronus cell cycle profile, the 2N peak is generally 
the highest, indicating that most of the cells are in G0/G1. This is observed in cells treated with 
DMSO for 24 hours, which displays a tall G0/G1 peak and a shorter G2/M peak separated by an 
intermediate S-phase population. A similar cell cycle profile is observed in for the 48 hr DMSO-
treated sample, showing that cells are dividing similarly at both time points. For EWS502 cells 
treated with UNC0621 for 24 hr, the cell cycle profile was similar to the corresponding DMSO-
treated sample, with the similar proportions in each phase of the cell cycle. However, after 48 
hours of UNC0621 treatment, I observed a marked decrease in the S-phase population relative to 
cells treated with DMSO. This corresponded to an increase in the G0/G1 population, indicating 
that after 48 hr incubation with UNC0621, cells were accumulating in G1 and unable to progress 
through S-phase.  
To confirm the effect of UNC0621 on cell cycle progression, I sought to test the effect of 
dose on the cell cycle profile. I treated EWS502 cells with 5, 2.5, 1.25, or 0.625 μM of 
UNC0621 for 72 hours, then stained with PI and performed cell cycle analysis by flow 
cytometry. DMSO alone was used as a control. I observed that UNC0621 caused a dose-
dependent decrease in the S-phase population, with 5 μM-treated cells having very few cells in 
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S-phase and the most cells in G0/G1. This further supports that UNC0621 induces a G0/G1 cell 
cycle arrest in Ewing sarcoma cells. 
Although UNC0621 appeared to arrest cell cycle progression as measured by PI staining, 
the S-phase population is in fact approximated by DNA content. Therefore, I wanted to 
quantitatively measure the percentage of cells in S-phase using bromodeoxyuridine (BrdU) 
incorporation. BrdU is a thymidine analog that is incorporated into replicating DNA, and can be 
detected using antibodies against BrdU, allowing for determination of cells in S-phase at the time 
of staining. BrdU staining can be combined with a stain for total DNA, in this case 7-AAD. 
Similar to PI, 7-AAD is a fluorescent intercalating agent, and as such is used to discern different 
phases of the cell cycle by DNA content. In a dividing cell population, S-phase cells with 
intermediate 7-AAD signal display an increase in BrdU signal after the 2N population, then 
signal decreases approaching the 4N population.  
I hypothesized that cells treated with UNC0621 for longer periods of time (48 or 72 hr) 
would have a decreased BrdU-positive population than control cells. To test this, I treated 
EWS502 cells with DMSO or 5 uM UNC0621 for 24, 48, or 72 hours, followed by a pulse with 
BrdU to label cells undergoing DNA replication. I also stained cells with 7-AAD to measure 
total DNA, then analyzed by flow cytometry. In 24 hr DMSO-treated cells, I observed the 2N 
(G0/G1) and 4N (G2/M) populations by low and high 7-AAD signal. These populations were 
also negative for BrdU incorporation. In between these populations I observed a BrdU-positive 
S-phase population, representing about 36% of captured events. 48 and 72 hr DMSO-treated 
samples show a similar pattern of BrdU incorporation, indicating that all DMSO-treated samples, 
regardless of treatment time, had comparable percentages of actively replicating cells at the time 
of staining. 
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Comparing the cells treated with UNC0621, the 24 hr sample exhibited a slightly lower 
percentage of BrdU-positive cells, about 24% of the population relative to 35% seen in 24 hr 
DMSO-treated cells. Strikingly, after 48 hours of UNC0621 treatment, the BrdU-positive 
population decreased to about 8% of the total population, and further to 4% after 72 hours of 
treatment. These data quantitatively demonstrate that UNC0621 treatment decreases active 
replication of Ewing sarcoma cells, and corroborates cell cycle profile experiments showing an 




My use of cell biological approaches has revealed that UNC0621 in an inducer of cell 
cycle arrest in Ewing sarcoma, rather than apoptosis. However, while cell lines that possess 




































































































































Fig 4.5: UNC0621 decreases the S-phase population of Ewing sarcoma cells. EWS502 
cells were treated with DMSO or 5 uM for the indicated period of time, then pulsed with 
BrdU for 1 hour. Cells were then harvested and fixed, and analyzed by flow cytometry. 
Representative experiment is shown. FITC-BrdU signal is on the y-axis, and 7-AAD signal 
is on the x-axis. Graphs depict quantification of BrdU-positive population. 
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sarcoma. Many other cell lines, including Jurkat, MSC, and SCCOHT also displayed sensitivity 
to UNC0621 comparable to that of Ewing sarcoma cells.  There are likely underlying biological 
differences or dependencies that dictate sensitivity to UNC0621, although this is not readily 
apparent. One current goal is to analyze alterations caused by UNC0621 to determine changes in 
genes or pathways that may mediate a cell cycle arrest phenotype. Moreover, changes detected 
by RNA-seq that are shared between sensitive cell lines may point to a biological mechanism for 




EWS894 and EWS502 cells (42) were cultured in RPMI-1640 supplemented with 15% 
FBS.  A673 cells were cultured in RPMI-1640 with 10% FBS. UMRC2 and 786-O cells were 
cultured in DMEM with sodium pyruvate, L-glutamine and 4.5 g/L glucose, supplemented with 
10% FBS. RPTEC cells were cultured using the REGM™ BulletKit™ (Lonza). HUVEC cells 
were cultured in the EGM™-2 BulletKit™ (Lonza) supplemented with 10% FBS and maintained 
at standard growth conditions of 37 °C and 5% CO2.  
 
Viability Assays 
Cell viability was assessed by WST-1 (Roche Applied Sciences) according to 
manufacturer’s recommendations. Absorbance was quantified at 450 nm and background scatter 
measured at 620 nm, with the latter value subtracted from 450 nm value to obtain the final 
absorbance. The background absorbance (media only) was subtracted from the mean of the 
triplicates for each condition.  Relative absorbance is expressed as a ratio of UNC0621-treated 
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over DMSO-treated. Error bars indicate standard deviation between three technical replicates. 
Cells counts were performed using a hemocytometer. 
 
Soft agar colony growth 
Cells were suspended in 0.5% low melting point agarose, 1X RPMI, 15% fetal bovine 
serum at a density of 4500 cells per well and layered over one mL of base agar (0.6% agarose, 
1X RPMI, 15% fetal bovine serum) in a 6-well dish. UNC0621 or DMSO was diluted in top agar 
layer to desired final concentration. Plates were overlayed with additional RPMI containing 
compound on day 5 and day 11. Plates were stained with MTT (0.5 mg/ml) on day 15 to 
visualize cell colonies.  
 
Apoptosis  
Cells were prepared and stained using BD Pharmingen™ FITC Annexin V Apoptosis 
Detection Kit and protocol (cat. No. 556547). Flow cytometry was performed immediately after 
staining (LSR II).  
 
Cell cycle analysis 
Treated cells were washed with PBS and fixed with 70% ice cold ethanol, then stained 
with PI. Flow cytometry was performed immediately after staining, collecting 10,000 total 
events at 100-200 events per second (CyAN, Beckman Coulter). 
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Chapter 5: Conclusions and Discussion 
In this study, we sought to identify and characterize small molecules that can reverse the 
chromatin signature mediated by the EWSR1-FLI1 oncogenic driver found in Ewing sarcoma, as 
discussed in Chapter 1. Using a novel chromatin-based screening approach, we discovered small 
molecule regulators of aberrant chromatin accessibility in Ewing sarcoma. While we focused our 
initial efforts on Ewing sarcoma, this approach could conceivably be applied to any cancer with a 
known chromatin signature.  
 Our screen identified histone deacetylase inhibitors (HDACi) as the primary compound 
class causing reversal of the oncogenic chromatin signature. This phenotype appears to be caused 
by the ability of HDACi to decrease transcription of the EWSR1-FLI1 fusion gene. Upon 
subsequent cursory examination of endogenous transcript levels of parental EWSR1 gene, we 
observed that HDACi treatment also decreased EWSR1 transcript levels. This mechanism of 
action points to a potential role of HDAC proteins in regulating transcript levels of EWSR1-FLI1 
via interaction with the EWSR1 promoter. To better understand this process, more work needs to 
be done in determining the regulatory factors that occupy the EWSR1 promoter. 
Additionally, we have identified UNC0621 as an inhibitor of chromatin accessibility and 
cell cycle progression in Ewing sarcoma. A looming concern is whether there is a link between 
the effect of UNC0621 on chromatin and on cell biology. UNC0621 seems to have an affinity for 
histone proteins, which are generally abundant across cell types. However, UNC0621 has a 
selective affect on cell proliferation. This discrepancy has several possible explanations. For 
instance, it is possible that UNC0621 derivatives bind ubiquitously to histones in vitro, but in 
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reality UNC0621 binds a subset of histones in cells. These could be marked by a post-
translational modification or by the presence of another regulatory factor that interacts with the 
compound. To determine this, we aim to perform in vivo Chem-seq to capture genome-wide 
interactions of the compound in vivo. Succeeding in this effort will provide insight into regions 
of the genome that may be selectively targeted by the UNC0621.  
 The biological determinants for sensitivity of a particular cell type to UNC0621 are still 
not understood. We have already performed RNA-seq in EWS894 cells and observed widespread 
changes in gene expression following treatment with UNC0621. We are currently performing 
RNA-seq in both sensitive and resistant cell lines following UNC0621 treatment to determine 
whether there are gene expression changes shared between cell lines that could begin to elucidate 
the mechanism of cell cycle arrest by UNC0621. 
 It is also possible that UNC0621 exhibits widespread binding across the genome, but only 
displays activity on certain regions of chromatin. To determine how UNC0621 affects chromatin 
accessibility genome-wide, we aim to perform FAIRE-seq in cells following treatment with 
UNC0621. Our attempts have been wrought with technical difficulties over the years, but we are 
now seeing signs of success and will soon be able to interrogate how UNC0621 regulates the 
epigenome. 
Yet another possible reason for our observations is that UNC0621 binds to a nucleosome-
associated protein target other than histones. Histones might appear frequently in our in vitro 
pull-downs due to their abundance, but it is possible they are not the primary biological target. 
Ongoing proteomic studies will provide candidates for biochemical targets of UNC0621. 
 Ultimately, our understanding of the function of chromatin-targeted small molecules 
would benefit greatest from comprehensive genomic characterization. Comparison of compound-
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induced chromatin and gene expression signatures across cell types can shed light on a 
compound’s mechanism of action and potential therapeutic utility. While we have begun this 
process for UNC0621, there are still many questions to be answered. Ideally UNC0621 can 
become a useful tool compound to study epigenetic processes important for certain cancers. 
Similar approaches for other chromatin-targeted small molecules will contribute to the study of 
cancers with epigenetic aberrations, both from a perspective of understanding regulatory 
mechanisms as well as creating potential for targeted therapies. 
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